Arbutus Biopharma (ABUS) 10-K28 Mar 142013 FY Annual reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
Document And Entity Information (USD $)	Dec. 31, 2013	Mar. 21, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'TEKMIRA PHARMACEUTICALS CORP	'	'
Document Type	'10-K	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Common Stock, Shares Outstanding	'	21,945,838	'
Entity Public Float	'	'	$67,789,985
Amendment Flag	'false	'	'
Entity Central Index Key	'0001447028	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Non-accelerated Filer	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets(CAD)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	68,716,531	47,024,124
Accounts receivable	116,556	1,074,891
Accrued revenue	212,384	2,373,881
Deferred expenses	172,952	431,410
Investment tax credits receivable	40,200	9,875
Prepaid expenses and other assets	1,084,030	329,280
Total current assets	70,342,653	51,243,461
Property and equipment (note 4)	13,038,751	13,188,186
Less accumulated depreciation (note 4)	-11,665,594	-11,836,456
Property and equipment, net of accumulated depreciation (note 4)	1,373,157	1,351,730
Total assets	71,715,810	52,595,191
Current liabilities:	'	'
Accounts payable and accrued liabilities (note 10)	3,680,462	3,795,546
Deferred revenue (note 3)	3,463,255	3,143,580
Warrants (note 2 and 5)	5,378,772	4,014,821
Total current liabilities	12,522,489	10,953,947
Deferred revenue, net of current portion (note 3)	'	722,445
Total liabilities	12,522,489	11,676,392
Stockholdersâ€™ equity:	'	'
Issued and outstanding: 19,048,900 (December 31, 2012 - 14,305,356)	216,701,859	181,785,818
Additional paid-in capital	25,343,481	24,786,028
Deficit	-167,026,633	-152,962,407
Accumulated other comprehensive income (loss)	-15,825,386	-12,690,640
Total stockholders' equity	59,193,321	40,918,799
Total liabilities and stockholders' equity	71,715,810	52,595,191

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (CAD)	Dec. 31, 2013	Dec. 31, 2012
Common shares, shares issued	19,048,900	14,305,356
Common shares, shares outstanding	19,048,900	14,305,356
Common shares, no par value (in Dollars per share)	'	'
Common shares, authorized	'	'

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Income (Loss) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenue (note 3)	'	'	'
Collaborations and contracts	$10,424,569	$12,105,186	$16,311,590
Licensing fees, milestone and royalty payments	5,039,581	2,000,000	500,000
Total revenue	15,464,150	14,105,186	16,811,590
Research, development, collaborations and contracts	21,458,258	18,043,356	20,131,922
General and administrative	5,546,273	8,140,779	6,386,386
Depreciation of property and equipment	612,837	865,599	986,932
Total expenses	27,617,368	27,049,734	27,505,240
Loss from operations	-12,153,218	-12,944,548	-10,693,650
Other income (losses)	'	'	'
Interest income	539,996	138,320	126,314
Licensing settlement payment (note 3(b))	'	65,000,000	'
Licensing settlement legal fees (note 3(b))	'	-18,737,966	'
Foreign exchange gains (losses)	1,079,310	24,855	-14,692
Warrant issuance costs (note 5)	'	-47,030	-80,937
(Increase) decrease in fair value of warrant liability (note 2)	-3,530,314	-3,821,635	579,474
Net income (loss)	-14,064,226	29,611,996	-10,083,491
Income (loss) per common share (note 2)	'	'	'
Basic (in Dollars per share)	($0.92)	$2.16	($0.89)
Diluted (in Dollars per share)	($0.92)	$2.07	($0.89)
Weighted average number of common shares	'	'	'
Basic (in Shares)	15,302,680	13,727,925	11,318,766
Diluted (in Shares)	15,302,680	14,320,814	11,318,766
Comprehensive income (loss)	'	'	'
Cumulative translation adjustment	-3,134,746	473,825	-53,066
Comprehensive income (loss)	($17,198,972)	$30,085,821	($10,136,557)

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Total
Consolidated Statement of Stockholders' Equity	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)
Balance, at Dec. 31, 2010	$172,982,011	$23,410,834	($172,490,912)	($13,111,399)	$10,790,534
Balance, (shares) (in Shares) at Dec. 31, 2010	10,338,702	'	'	'	'
Stock-based compensation	'	633,449	'	'	633,449
Issuance of common shares pursuant to exercise of options	128,371	-117,586	'	'	10,785
Issuance of common shares pursuant to exercise of options (shares) (in Shares)	20,033	'	'	'	'
Issuance of common shares in conjunction with the public offering, net of issuance costs and net of initial fair value of warrants	3,928,294	'	'	'	3,928,294
Issuance of common shares in conjunction with the public offering, net of issuance costs and net of initial fair value of warrants (shares) (in Shares)	1,789,900	'	'	'	'
Currency translation adjustment	'	'	'	-53,066	-53,066
Net Income (loss)	'	'	-10,083,491	'	-10,083,491
Balance, at Dec. 31, 2011	177,038,676	23,926,697	-182,574,403	-13,164,465	5,226,505
Balance, (shares) (in Shares) at Dec. 31, 2011	12,148,635	'	'	'	'
Stock-based compensation	'	982,290	'	'	982,290
Issuance of common shares pursuant to exercise of options	194,050	-122,959	'	'	71,091
Issuance of common shares pursuant to exercise of options (shares) (in Shares)	38,635	'	'	'	'
Issuance of common shares pursuant to exercise of warrants	1,512,973	'	'	'	1,512,973
Issuance of common shares pursuant to exercise of warrants (in Shares)	269,485	'	'	'	'
Issuance of common shares in conjunction with the public offering, net of issuance costs and net of initial fair value of warrants	3,040,119	'	'	'	3,040,119
Issuance of common shares in conjunction with the public offering, net of issuance costs and net of initial fair value of warrants (shares) (in Shares)	1,848,601	'	'	'	'
Currency translation adjustment	'	'	'	473,825	473,825
Net Income (loss)	'	'	29,611,996	'	29,611,996
Balance, at Dec. 31, 2012	181,785,818	24,786,028	-152,962,407	-12,690,640	40,918,799
Balance, (shares) (in Shares) at Dec. 31, 2012	14,305,356	'	'	'	'
Stock-based compensation	'	903,005	'	'	903,005
Issuance of common shares pursuant to exercise of options	734,872	-345,552	'	'	389,320
Issuance of common shares pursuant to exercise of options (shares) (in Shares)	125,596	'	'	'	'
Issuance of common shares pursuant to exercise of warrants	2,142,852	'	'	'	2,142,852
Issuance of common shares pursuant to exercise of warrants (in Shares)	305,448	'	'	'	'
Issuance of common shares in conjunction with the public offering, net of issuance costs and net of initial fair value of warrants	32,038,317	'	'	'	32,038,317
Issuance of common shares in conjunction with the public offering, net of issuance costs and net of initial fair value of warrants (shares) (in Shares)	4,312,500	'	'	'	'
Currency translation adjustment	'	'	'	-3,134,746	-3,134,746
Net Income (loss)	'	'	-14,064,226	'	-14,064,226
Balance, at Dec. 31, 2013	$216,701,859	$25,343,481	($167,026,633)	($15,825,386)	$59,193,321
Balance, (shares) (in Shares) at Dec. 31, 2013	19,048,900	'	'	'	'

Consolidated_Statement_of_Stoc1

Consolidated Statement of Stockholders' Equity (Parentheticals) (Accumulated Other Comprehensive Income (Loss) [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accumulated Other Comprehensive Income (Loss) [Member]	'	'	'
Issuance of common shares, issuance costs	$2,461,683	$178,521	$481,135
Issuance of common shares, initial fair value of warrants	'	$850,907	$751,505

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flow	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	USD ($)	USD ($)	USD ($)
OPERATING ACTIVITIES	'	'	'
Income (loss) for the year	($14,064,226)	$29,611,996	($10,083,491)
Items not involving cash:	'	'	'
Depreciation of property and equipment	612,837	865,599	986,932
Stock-based compensation expense	903,005	982,290	633,449
Unrealized foreign exchange (gains) losses	-18,119	29,292	-20,331
Warrant issuance costs	'	47,030	80,937
Change in fair value of warrant liability	3,530,314	3,821,635	-579,474
Fair value of warrants issued in conjunction with debt facility	'	'	35,414
Net change in non-cash operating items:	'	'	'
Accounts receivable	888,929	-189,707	2,397,321
Accrued revenue	2,008,215	-2,187,580	621,552
Deferred expenses	230,602	360,720	-226,999
Investment tax credits receivable	-30,963	322,845	71,336
Inventory	'	'	148,214
Prepaid expenses and other assets	-776,012	97,272	-107,504
Accounts payable and accrued liabilities	129,997	-197,265	-2,142,976
Deferred revenue	-153,138	-655,344	354,662
Net cash (used in) operating activities	-6,738,559	32,908,783	-7,830,958
INVESTING ACTIVITIES	'	'	'
Proceeds from sale of property and equipment	'	2,503	'
Acquisition of property and equipment	-725,100	-14,900	-60,378
Net cash used in investing activities	-725,100	-12,397	-60,378
FINANCING ACTIVITIES	'	'	'
Proceeds from issuance of common shares and warrants, net of issuance costs	32,038,317	3,843,996	4,598,862
Issuance of common shares pursuant to exercise of options	389,320	71,091	10,786
Issuance of common shares pursuant to exercise of warrants	288,824	632,282	'
Net cash provided by financing activities	32,716,461	4,547,369	4,609,648
Effect of foreign exchange rate changes on cash & cash equivalents	-3,560,395	549,610	-100,232
Increase (decrease) in cash and cash equivalents	21,692,407	37,993,365	-3,381,920
Cash and cash equivalents, beginning of year	47,024,124	9,030,759	12,412,678
Cash and cash equivalents, end of year	68,716,531	47,024,124	9,030,759
Supplemental cash flow information	'	'	'
Fair value of warrants exercised on a cashless basis	1,404,349	210,680	'
Investment tax credits received	9,875	322,720	103,664
Fair value of warrants issued in conjunction with public offering	'	850,907	751,505
Fair value of warrants issued in conjunction with debt facility	'	'	$35,414

Note_1_Nature_of_Business_and_

Note 1 - Nature of Business and Future Operations	12 Months Ended
Note 1 - Nature of Business and Future Operations	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Nature of Operations [Text Block]	'
	1. Nature of business and future operations

	Tekmira Pharmaceuticals Corporation (the “Company”) is a Canadian biopharmaceutical business focused on advancing novel RNA interference therapeutics.

	The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The continuation of the research and development activities and the commercialization of its products are dependent on the Company’s ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of future research and development programs or the Company’s ability to fund these programs in the future.

Note_2_Significant_Accounting_

Note 2 - Significant Accounting Policies	12 Months Ended
Note 2 - Significant Accounting Policies	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	2. Significant accounting policies

	Basis of presentation

	Tekmira Pharmaceuticals Corporation was incorporated on October 6, 2005 as an inactive wholly owned subsidiary of Inex Pharmaceuticals Corporation (“Inex”). Pursuant to a “Plan of Arrangement” effective April 30, 2007 the business and substantially all of the assets and liabilities of Inex were transferred to the Company. The consolidated financial statements for all periods presented herein include the consolidated operations of Inex until April 30, 2007 and the operations of the Company thereafter.

	These consolidated financial statements include the accounts of the Company and its two wholly-owned subsidiaries, Protiva Biotherapeutics Inc. and Protiva Biotherapeutics (USA), Inc., which were acquired on May 30, 2008. All intercompany transactions and balances have been eliminated on consolidation.

	Comparative Information

	Certain information has been reclassified to conform with the financial statement presentation adopted for the current year.

	Use of estimates

	The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, revenue, expenses, contingent assets and contingent liabilities as at the end or during the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring the use of management estimates relate to recognition of revenue, stock-based compensation, share purchase warrant valuation and the amounts recorded as accrued liabilities.

	Cash and cash equivalents

	Cash and cash equivalents are all highly liquid instruments with an original maturity of three months or less when purchased. Cash equivalents are recorded at cost plus accrued interest. The carrying value of these cash equivalents approximates their fair value.

	Fair value of financial instruments

	We measure certain financial instruments and other items at fair value.

	To determine the fair value, we use the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:

		•		Level 1 inputs are quoted market prices for identical instruments available in active markets.

		•		Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.

		•		Level 3 inputs are unobservable inputs for the asset or liability and will reflect management’s assumptions about market assumptions that would be used to price the asset or liability.

	Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.

	The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, investment tax credits receivable, accounts payable and accrued liabilities, and warrants and promissory notes.

	The carrying values of cash and cash equivalents are recorded at fair value based on quoted prices in active markets. The carrying values of accounts receivable, investment tax credits receivable and accounts payable and accrued liabilities approximate their fair values due to the immediate or short-term maturity of these financial instruments.

	As quoted prices for the warrants are not readily available, the Company has used a Black-Scholes pricing model, as described in Note 5, to estimate fair value. These are level 3 inputs as defined above.

	The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:

			Level 1			Level 2			Level 3			31-Dec-13
	Assets
	Cash		$	68,716,531			-			-		$	68,716,531
	Guaranteed Investment Certificates			-			-			-			-
	Total		$	68,716,531			-			-		$	68,716,531

	Liabilities
	Warrants		$	-			-		$	5,378,772		$	5,378,772

			Level 1			Level 2			Level 3			31-Dec-12
	Assets
	Cash		$	44,373,720			-			-		$	44,373,720
	Guaranteed Investment Certificates			2,650,404			-			-			2,650,404
	Total		$	47,024,124			-			-		$	47,024,124

	Liabilities
	Warrants		$	-			-		$	4,014,821		$	4,014,821

	The following table presents the changes in fair value of the Company’s warrants:

			Liability at			Opening			Fair value of			Increase			Foreign			Liability
beginning			liability of			warrants			(decrease) in			exchange			at end
of the year			warrants issued in			exercised			value of			(gain) loss			of the year
			the year			in the			warrants
						year

Year ended December 31, 2011			$	-		$	786,919		$	-		$	(579,474	)	$	(5,825	)	$	201,620
Year ended December 31, 2012			$	201,620		$	850,907		$	(880,691	)	$	3,821,635		$	21,350		$	4,014,821
Year ended December 31, 2013			$	4,014,821		$	-		$	(1,854,028	)	$	3,530,314		$	(312,335	)	$	5,378,772

Inventory

Inventory includes materials assigned for the manufacture of products for collaborative partners and manufacturing costs for products awaiting acceptance by collaborative partners. Inventory is carried at the lower of cost and net realizable value. The cost of inventories includes all costs of purchase, costs of manufacturing and other costs incurred in bringing the inventories to their present location and condition.

Materials purchased for the Company’s own research and development products, or, for collaborative partners where an acceptance criteria does not apply, are not recorded as inventory but are expensed at the time of receipt.

Property and equipment

Property and equipment is recorded at cost less impairment losses, accumulated depreciation, related government grants and investment tax credits. The Company records depreciation using the straight-line method over the estimated useful lives of the capital assets as follows:

	Rate

Laboratory equipment (years)		5
Computer and office equipment (years)	2	-	5
Furniture and fixtures (years)		5

Leasehold improvements are depreciated over their estimated useful lives but in no case longer than the lease term, except where lease renewal is reasonably assured. Assets held under capital leases that do not allow for ownership to pass to the Company are depreciated using the straight-line method over their useful life, not exceeding the lease term. Assets under construction are not depreciated until usage has begun.

Intangible assets

The costs incurred in establishing and maintaining patents for intellectual property developed internally are expensed in the period incurred.

Impairment of long-lived assets

If there is a major event indicating that the carrying value of property and equipment may be impaired then management will perform an impairment test and if the recoverable value, based on undiscounted future cash flows, exceeds carrying value then such assets are written down to their fair values.

Revenue recognition

The Company earns revenue from research and development collaboration and contract services, licensing fees and milestone payments. Revenues associated with multiple element arrangements are attributed to the various elements based on their relative fair values or are recognized as a single unit of accounting when relative fair values are not determinable. Non-refundable payments received under collaborative research and development agreements are recorded as revenue as services are performed and related expenditures are incurred. Non-refundable upfront license fees from collaborative licensing and development arrangements are recognized as the Company fulfills its obligations related to the various elements within the agreements, in accordance with the contractual arrangements with third parties and the term over which the underlying benefit is being conferred. Revenue earned under contractual arrangements upon the occurrence of specified milestones is recognized as the milestones are achieved and collection is reasonably assured.

Revenue earned under research and development manufacturing collaborations where the Company bears some or all of the risk of a product manufacturing failure is recognized when the purchaser accepts the product and there are no remaining rights of return.

Revenue earned under research and development collaborations where the Company does not bear any risk of product manufacturing failure is recognized in the period the work is performed. For contracts where the manufacturing amount is specified, revenue is recognized as product is manufactured in proportion to the total amount specified under the contract.

Revenue and expenses under the contract with the United States Government Department of Defense (“DoD”) are being recorded using the percentage-of-completion method. Contract progress is based on costs incurred to date. Expenses under the contract are recorded in the Company’s consolidated statement of operations and comprehensive income (loss) as they are incurred. Government contract revenues related to expenses incurred under the contract are recorded in the same period as those expenses. Expenses accrued under the contract but not yet invoiced are recorded in the Company’s balance sheet as accrued liabilities and accrued revenues. Equipment purchased under the contract is recorded on the Company’s balance sheet as deferred expense and deferred revenue and amortized, on a straight-line basis, over the life of the contract.

Cash or other compensation received in advance of meeting the revenue recognition criteria is recorded on the balance sheet as deferred revenue. Revenue meeting recognition criteria but not yet received or receivable is recorded on the balance sheet as accrued revenue.

Leases and lease inducements

Leases entered into are classified as either capital or operating leases. Leases which substantially transfer all benefits and risks of ownership of property to the Company are accounted for as capital leases. At the time a capital lease is entered into, an asset is recorded together with its related long-term obligation to reflect the purchase and financing.

All other leases are accounted for as operating leases wherein rental payments are expensed as incurred.

Lease inducements represent leasehold improvement allowances and reduced or free rent periods and are amortized on a straight-line basis over the term of the lease and are recorded as a reduction of rent expense.

Research and development costs

Research and development costs, including acquired in-process research and development expenses for which there is no alternative future use, are charged as an expense in the period in which they are incurred.

Income or loss per share

Income or loss per share is calculated based on the weighted average number of common shares outstanding. Diluted loss per share does not differ from basic loss per share since the effect of the Company’s stock options and warrants is anti-dilutive. Diluted income per share is calculated using the treasury stock method which uses the weighted average number of common shares outstanding during the period and also includes the dilutive effect of potentially issuable common shares from outstanding, in-the-money stock options and warrants.

The following table sets out the computation of basic and diluted net income (loss) per common share:

		Year ended December 31
		2013			2012			2011
Numerator:
Net income (loss)		$	(14,064,226	)	$	29,611,996		$	(10,083,491	)
Denominator:
Weighted average number of common shares			15,302,680			13,727,925			11,318,766
Effect of dilutive securities:
Warrants			-			177,374			-
Options			-			415,515			-
Diluted weighted average number of common shares			15,302,680			14,320,814			11,318,766

Basic income (loss) per common share		$	(0.92	)	$	2.16		$	(0.89	)

Diluted income (loss) per common share		$	(0.92	)	$	2.07		$	(0.89	)

For the year ended December 31, 2013, potential common shares of 3,064,767 were excluded from the calculation of income per common share because their inclusion would be anti-dilutive (December 31, 2012 –1,085,503; December 31, 2011 – 2,694,330).

Government grants and refundable investment tax credits

Government grants and tax credits provided for current expenses is included in the determination of income or loss for the year, as a reduction of the expenses to which it relates. Government grants and tax credits towards the acquisition of property and equipment is deducted from the cost of the related property and equipment.

Foreign currency translation and change in reporting currency

The functional currency of the Company is the Canadian dollar. For the Company and its integrated subsidiaries (Protiva Biotherapeutics Inc. and Protiva Biotherapeutics (USA), Inc.), foreign currency monetary assets and liabilities are translated into Canadian dollars at the rate of exchange prevailing at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. The previous month’s closing rate of exchange is used to translate revenue and expense transactions. Exchange gains and losses are included in income or loss for the period.

Effective October 1, 2013, the Company is using United States dollars as its reporting currency. All assets and liabilities are translated using the exchange rate at the balance sheet date (2013 – 0.9402; 2012 – 1.0051; 2011 – 0.9833). Revenues, expenses and other income (losses) are translated using the average rate for the period (2013 – 0.971; 2012 – 1.001; 2011 – 1.012), except for large transactions, for which the exchange rate on the date of the transaction is used. Equity accounts are translated using the historical rate. As a result of the change in reporting currency, the Company is reporting an accumulated other comprehensive loss of $15,825,386 as at December 31, 2013 (2012 - $12,690,640; 2011 – $13,164,466) in its consolidated balance sheets. As the translation differences from the Company’s functional currency of Canadian dollars to the Company’s reporting currency of U.S. dollars are unrealized gains and losses, the differences are recorded in other comprehensive income (loss), and do not impact the calculation of Earnings per Share.

Deferred income taxes

Income taxes are accounted for using the asset and liability method of accounting. Deferred income taxes are recognized for the future income tax consequences attributable to differences between the carrying values of assets and liabilities and their respective income tax bases and for loss carry-forwards. Deferred income tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the periods in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax laws or rates is included in earnings in the period that includes the enactment date. When realization of deferred income tax assets does not meet the more-likely-than-not criterion for recognition, a valuation allowance is provided.

Stock-based compensation

The Company grants stock options to employees and directors pursuant to a share incentive plan described in note 5. Compensation expense is recorded for issued stock options using the fair value method with a corresponding increase in additional paid-in capital. Any consideration received on the exercise of stock options is credited to share capital.

The fair value of stock options is measured at the grant date and amortized on a straight-line basis over the vesting period.

Warrants

The Company accounts for the warrants under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company’s own stock, on the understanding that in compliance with applicable securities laws, the registered warrants require the issuance of registered securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. The Company classifies warrants in its consolidated balance sheet as a liability which is revalued at each balance sheet date subsequent to the initial issuance. The Company uses the Black-Scholes pricing model to value the warrants. Determining the appropriate fair-value model and calculating the fair value of registered warrants requires considerable judgment. A small change in the estimates used may cause a relatively large change in the estimated valuation. The estimated volatility of the Company’s common stock at the date of issuance, and at each subsequent reporting period, is based on historic fluctuations in the Company’s stock price. The risk-free interest rate is based on the zero-coupon rate for bonds with a maturity similar to the expected remaining life of the warrants at the valuation date. The expected life of the warrants is based on the historical pattern of exercises of warrants.

Segment information

The Company operates in a single reporting segment, the research and development of RNA interference therapeutics. Substantially all of the Company’s revenues to date were earned from customers or collaborators based in the United States. Substantially all of the Company’s premises, property and equipment is located in Canada.

Recent accounting pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.

In December 2011, the FASB issued ASU 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities. In January 2013, the FASB issued ASU-2013-01, Balance Sheet: Clarifying the Scope and Disclosures about Offsetting Assets and Liabilities, which narrows the scope of ASU 2011-011. These newly issued accounting standards requires an entity to disclose both gross and net information about instruments and transactions eligible for offset in the balance sheet as well as instruments and transactions executed under a master netting or similar arrangement and was issued to enable users of financial statements to understand the effects or potential effects of those arrangements on its balance sheet. This ASU is required to be applied retrospectively and is effective for fiscal years, and interim periods within those years, beginning on or after January 1, 2013. As this accounting standard only requires enhanced disclosure, the adoption of this standard did not have an impact on the Company’s financial position or statement of operations.

In February 2013, the FASB issued amendments to the accounting guidance for presentation of comprehensive income to improve the reporting of reclassifications out of accumulated other comprehensive income. The amendments do not change the current requirements for reporting net income or other comprehensive income, but do require an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the statement where the net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under GAAP to be reclassified to net income in its entirety in the same reporting period. For other amounts that are not required under GAAP to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures required under GAAP that provide additional detail about these amounts. For public companies, these amendments are effective prospectively for reporting periods beginning after December 15, 2012. The adoption of this guidance did not impact our consolidated financial statements.

In July 2013, the FASB issued ASU 2013-11, Income Taxes (ASC 740) Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carry forward, a Similar Tax Loss, or a Tax Credit Carry forward Exists (Update). The update is intended to eliminate the diversity in practice of the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The update is effective for annual and interim financial statements for fiscal years beginning after December 15, 2013. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted.

Note_3_Collaborations_Contract

Note 3 - Collaborations, Contracts and Licensing Agreements	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Collaborative Arrangement Disclosure [Text Block]	'
	3. Collaborations, contracts and licensing agreements

	The following tables set forth revenue recognized under collaborations, contracts and licensing agreements:

	Revenue

		Year ended December 31
		2013		2012		2011
	Collaborations and contracts
	DoD (a)	$	9,805,556	$	11,536,101	$	11,565,997
	Alnylam (b)		-		9,719		4,191,295
	BMS (c)		525,527		440,279		437,165
	Other RNAi collaborators (d)		93,486		119,087		117,133
	Total research and development collaborations and contracts		10,424,569		12,105,186		16,311,590
	Licensing fees and milestone payments
	Alnylam milestone payments (b)		5,000,000		1,000,000		500,000
	Spectrum payments (e)		39,581		1,000,000		-
	Total licensing fees and milestone payments		5,039,581		2,000,000		500,000
	Total revenue	$	15,464,150	$	14,105,186	$	16,811,590

	The following table sets forth deferred collaborations and contracts revenue:

		31-Dec-13		31-Dec-12

	DoD (a)	$	1,655,028	$	1,388,970
	BMS current portion (c)		1,808,227		1,754,610
	Deferred revenue, current portion		3,463,255		3,143,580
	BMS long-term portion (c)		-		722,445
	Total deferred revenue	$	3,463,255	$	3,866,025

	(a) Contract with United States Government’s Department of Defense (“DoD”) to develop TKM-Ebola

	On July 14, 2010, the Company signed a contract with the DoD to advance TKM-Ebola, an RNAi therapeutic utilizing the Company’s lipid nanoparticle technology to treat Ebola virus infection.

	In the initial phase of the contract, funded as part of the Transformational Medical Technologies program, the Company is eligible to receive up to $34.7 million. This initial funding is for the development of TKM-Ebola including completion of preclinical development, filing an Investigational New Drug application with the United States Food and Drug Administration (“FDA”) and completing a Phase 1 human safety clinical trial. On May 8, 2013, the Company announced that the contract had been modified to support development plans that integrate recent advancements in lipid nanoparticle (“LNP”) formulation and manufacturing technologies. The contract modification increased the stage one targeted funding to $41.7 million.

	The DoD has the option of extending the contract beyond the initial funding period to support the advancement of TKM-Ebola through to the completion of clinical development and FDA approval. Based on the contract’s budget this would provide the Company with up to $140.0 million in funding for the entire program.

	Under the contract, the Company is reimbursed for costs incurred, including an allocation of overhead costs, and is paid an incentive fee. At the beginning of the fiscal year the Company estimates its labour and overhead rates for the year ahead. At the end of the year the actual labour and overhead rates are calculated and revenue is adjusted accordingly. The Company’s actual labour and overhead rates will differ from its estimated rates based on actual costs incurred and the proportion of the Company’s efforts on contracts and internal products versus indirect activities. Within minimum and maximum collars, the amount of incentive fee the Company can earn under the contract varies based on costs incurred versus budgeted costs. During the contractual period, incentive fee revenue and total costs are impacted by management’s estimate and judgments which are continuously reviewed and adjusted as necessary using the cumulative catch-up method. At December 31, 2012, the Company was not able to make a reliable estimate of the final contract costs, and only the minimum incentive fee achievable and earned was recognized. At December 31, 2013, the Company believes it can reliably estimate the final contract costs so has recognized the portion of expected incentive fee which has been earned to date.

	On August 6, 2012, the Company announced that it had received a temporary stop-work order from the DoD in respect of this contract. On October 2, 2012, the Company announced that the stop-work order had been lifted and work on the contract resumed. On November 1, 2012, the Company submitted a contract modification request to the DoD in order to integrate recent advancements in the Company’s formulation technology. The modification request is currently being negotiated while work is continuing on the contract.

	(b) License and collaboration with Alnylam Pharmaceuticals, Inc. (“Alnylam”)

	License and Collaboration Agreement with Alnylam through Tekmira

	On January 8, 2007, the Company entered into a licensing and collaboration agreement with Alnylam (“Alnylam License and Collaboration”), which was amended and restated in May 2008, giving them an exclusive license to certain of the Company’s historical lipid nanoparticle intellectual property for the discovery, development, and commercialization of ribonucleic acid interference (“RNAi”) therapeutics.

	The Alnylam License and Collaboration was replaced by a new license agreement as part of the settlement, which is discussed below.

	Cross-License with Alnylam acquired through Protiva

	As a result of the acquisition of Protiva on May 30, 2008, the Company acquired a Cross-License Agreement between Protiva and Alnylam (the “Alnylam Cross-License”). Alnylam was granted a non-exclusive license to the Protiva intellectual property.

	The Alnylam Cross-License was replaced by a new license agreement as part of the settlement, which is discussed below.

	Manufacturing agreement with Alnylam

	Under a manufacturing agreement with Alnylam (the “Alnylam Manufacturing Agreement”) effective January 1, 2009, the Company was the exclusive manufacturer of any products required by Alnylam through to the end of Phase 2 clinical trials that utilize the Company’s technology. Alnylam was paying the Company for the provision of staff and for external costs incurred. Time charged to Alnylam was at a fixed rate and under the Alnylam Manufacturing Agreement there was a contractual minimum for the provision of staff of $11,200,000 over the three year period ending December 31, 2011.

	The Alnylam Manufacturing Agreement was terminated as part of the settlement which is discussed below.

	Settlement of litigation with Alnylam and Acuitas Therapeutics Inc. (“Acuitas”, formerly AlCana Technologies Inc.)

On March 16, 2011 the Company filed a complaint against Alnylam. On November 12, 2012, the Company entered into an agreement to settle all litigation between the Company and Alnylam and Acuitas (the “Settlement”) and also entered into a new licensing agreement with Alnylam that replaces all earlier licensing, cross-licensing, collaboration, and manufacturing agreements. The Company entered into a separate cross license agreement with Acuitas which includes milestone and royalty payments and Acuitas has agreed not to compete in the RNAi field for five years. In conjunction with the Settlement, the Company paid Acuitas $300,000. The Company paid a further $1,500,000 upon the execution of the cross license agreement with Acuitas, in the year ended December 31, 2013.

As a result of the new Alnylam license agreement, on November 26, 2012, the Company received $65,000,000 in cash from Alnylam. This includes $30,000,000 associated with the termination of the manufacturing agreement and $35,000,000 associated with the termination of the previous license agreements, as well as a modification of the milestone and royalty schedules associated with Alnylam's ALN-VSP, ALN-PCS, and ALN-TTR programs. Under the settlement, Alnylam received license rights to the Company’s patents that were filed, or that claim priority to a patent that was filed, before April 15, 2010. Alnylam does not have rights to the Company’s patents filed after April 15, 2010 unless they claim priority to a patent filed before that date. In addition, Alnylam has transferred all agreed upon patents and patent applications related to lipid nanoparticle (“LNP”) technology for the systemic delivery of RNAi therapeutic products, including the MC3 lipid family, to the Company, who will own and control prosecution of this intellectual property portfolio. The Company is the only entity able to sublicense its LNP intellectual property in future platform-type relationships. Alnylam has a license to use the Company’s intellectual property to develop and commercialize products and may only grant access to the Company’s LNP technology to its partners if it is part of a product sublicense. Alnylam will pay the Company milestones and royalties as Alnylam’s LNP-enabled products are developed and commercialized.

The new licensing agreement with Alnylam also grants the Company intellectual property rights to develop its own proprietary RNAi therapeutics. Alnylam has granted the Company a worldwide license for the discovery, development and commercialization of RNAi products directed to thirteen gene targets – three exclusive and ten non-exclusive licenses – provided that they have not been committed by Alnylam to a third party or are not otherwise unavailable as a result of the exercise of a right of first refusal held by a third party or are part of an ongoing or planned development program of Alnylam. Licenses for five of the ten non-exclusive targets – ApoB, PLK1, Ebola, WEE1, and CSN5 – have already been granted, along with an additional license for ALDH2, which has been granted on an exclusive basis. In consideration for this license, the Company has agreed to pay single-digit royalties to Alnylam on product sales and have milestone obligations of up to $8,500,000 on the non-exclusive licenses (with the exception of TKM-Ebola, which has no milestone obligations). Alnylam no longer has “opt-in” rights to the Company’s lead oncology product, TKM-PLK1, so the Company now holds all development and commercialization rights related TKM-PLK1. The Company will have no milestone obligations on the three exclusive licenses. As a result of the settlement of the litigation between the Company and Alnylam, $18,737,966 in a contingent obligation payment to Orrick, Herrington and Sutcliffe LLP (“Orrick”), lead legal counsel for the lawsuit against Alnylam and Acuitas, was paid out on December 10, 2012.

Milestone receipts and payments

In June 2012 the Company earned a $1,000,000 milestone from Alnylam in respect of the initiation of Alnylam’s ALN-TTR02 Phase 2 human clinical trial.

In November 2013, Alnylam initiated a Phase III trial with ALN-TTR02, also known as patisiran, and the associated $5,000,000 development milestone was paid to the Company in December 2013.

In November 2013, the Company initiated Phase I/II clinical trial for TKM-PLK1, resulting in a milestone payment of $375,000 to Alnylam.

Arbitration with Alnylam and Ascletis Pharmaceuticals (Hangzhou) Co. Ltd. (“Ascletis”)

On June 21, 2013, the Company transferred manufacturing process technology to Ascletis to enable them to produce ALN-VSP, a product candidate licensed to them by Alnylam. The Company believes that under the new licensing agreement with Alnylam, the technology transfer to Ascletis triggers a $5,000,000 milestone obligation from Alnylam to the Company. However, Alnylam has demanded a declaration that the Company has not yet met its milestone obligations. The Company disputes Alnylam’s position. To remedy this dispute, the Company and Alnylam have commenced arbitration proceedings as provided for under the agreement. The Company has not recorded any revenue in respect of this milestone.

(c) Bristol-Myers Squibb (“BMS”) collaboration

On May 10, 2010 the Company announced the expansion of its research collaboration with BMS. Under the new agreement, BMS uses small interfering RNA (“siRNA”) molecules formulated by the Company in LNP technology to silence target genes of interest. BMS is conducting the preclinical work to validate the function of certain genes and share the data with the Company. The Company can use the preclinical data to develop RNAi therapeutic drugs against the therapeutic targets of interest. The Company received $3,000,000 from BMS concurrent with the signing of the agreement and recorded the amount as deferred revenue. The Company is required to provide a pre-determined number of LNP batches over the four-year agreement. BMS has a first right to negotiate a licensing agreement on certain RNAi products developed by the Company that evolve from BMS validated gene targets.

Revenue from the May 10, 2010 agreement with BMS is being recognized as the Company produces the related LNP batches.

As at December 31, 2013, the Company and BMS intend to extend the agreement’s end date from May 10, 2014 to December 31, 2014. Extending the agreement will give BMS more time to order LNP batches. There will not be any monetary consideration for extending the agreement. Revenue recognized in 2013 has been reduced and the balance of deferred revenue as at December 31, 2013 has been increased to account for BMS, potentially, ordering more batches under the agreement.

(d) Other RNAi collaborators

The Company has active research agreements with a number of other RNAi collaborators.

(e) Agreements with Spectrum Pharmaceuticals, Inc. (“Spectrum”)

On May 6, 2006, the Company signed a number of agreements with Talon Therapeutics, Inc. (“Talon”, formerly Hana Biosciences, Inc.) including the grant of worldwide licenses (the “Talon License Agreement”) for three of the Company’s chemotherapy products, Marqibo®, AlocrestTM (Optisomal Vinorelbine) and BrakivaTM (Optisomal Topotecan).

On August 9, 2012, the Company announced that Talon had received accelerated approval for Marqibo from the FDA for the treatment of adult patients with Philadelphia chromosome negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Marqibo is a liposomal formulation of the chemotherapy drug vincristine. In the year ended December 31, 2012, the Company received a milestone of $1,000,000 based on the FDA’s approval of Marqibo and will receive royalty payments based on Marqibo’s commercial sales. There are no further milestones related to Marqibo but the Company is eligible to receive total milestone payments of up to $18,000,000 on Alocrest and Brakiva.

Talon was acquired by Spectrum in July 2013. The acquisition does not affect the terms of the license between Talon and the Company.

On September 3, 2013, Spectrum announced that they had shipped the first commercial orders of Marqibo. In the year ended December 31, 2013, the Company recorded $39,581 in Marqibo royalty revenue (2012 - $nil, 2011 - $nil). In the year ended December 31, 2013, the Company accrued $990 in royalties due to TPC in respect of the Marqibo royalty earned by the Company (see note 8).

(f) License agreement with Merck & Co., Inc. (“Merck”)

As a result of the acquisition of Protiva in 2008, the Company received a non-exclusive royalty-bearing world-wide license, of certain intellectual property acquired by Merck. Under the license, Merck will pay up to $17,000,000 in milestones for each product it develops using the acquired intellectual property, except for the first product for which Merck will pay up to $15,000,000 in milestones. Merck will also pay royalties on product sales. Merck’s license rights are limited to patents that the Company filed, or that claim priority to a patent that was filed, before October 9, 2008. Merck does not have rights to patents filed by the Company after October 9, 2008 unless they claim priority to a patent filed before that date. The license agreement with Merck was entered into as part of a settlement of litigation between Protiva and a Merck subsidiary. No payments have been made under this license to date.

Merck has granted a license to the Company to certain of its intellectual property.

On January 12, 2014, Alnylam announced that they will be acquiring this license from Merck in which case this license agreement will transfer to Alnylam.

Note_4_Property_and_Equipment

Note 4 - Property and Equipment	12 Months Ended
Note 4 - Property and Equipment	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	4. Property and equipment

	31-Dec-13	Cost		Accumulated			Net
	31-Dec-13	Cost		depreciation			book value

	Lab equipment	$	4,885,963	$	(4,678,976	)	$	206,987
	Leashold improvements		5,592,312		(5,001,683	)	$	590,629
	Computer hardware and software		1,991,927		(1,589,519	)	$	402,408
	Furniture and fixtures		395,948		(395,416	)	$	532
	Assets under construction		172,601		-		$	172,601
		$	13,038,751	$	(11,665,594	)	$	1,373,157

	31-Dec-12	Cost		Accumulated			Net
	31-Dec-12	Cost		depreciation			book value

	Lab equipment	$	5,136,975	$	(4,787,905	)	$	349,070
	Leasehold improvements		5,978,338		(5,041,900	)		936,438
	Computer hardware and software		1,649,593		(1,585,288	)		64,305
	Furniture and fixtures		423,281		(421,363	)		1,918
		$	13,188,187	$	(11,836,456	)	$	1,351,731

	As at December 31, 2013, all of the Company’s property and equipment are currently in use and no impairment has been recorded.

Note_5_Share_Capital

Note 5 - Share Capital	12 Months Ended
Note 5 - Share Capital	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'


	5. Share capital

	(a) Financing

	On June 16, 2011, the Company completed a public offering of 1,789,900 units at a price of $2.88 (C$2.85) each for total gross proceeds, before expenses, of $5,160,934. Each unit consists of one common share and one half of one common share purchase warrant. Each whole warrant entitles the holder to acquire one common share at a price of C$3.35. The warrants expire on June 15, 2016. After paying underwriter’s commission and other unit issue costs, the offering generated net cash of $4,598,862. The total unit issuance cost of $562,072 has been allocated, on a pro-rata basis, as $481,135 to the shares and $80,937to the warrants and recorded, respectively, to share capital and warrant issuance costs in the consolidated statement of operations and comprehensive income (loss).

	On the date of issuance, the Black-Scholes aggregate value of the 894,950 warrants was $751,505 based on an assumed risk-free interest rate of 2.19%, volatility of 40%, a zero dividend yield and an expected life of 5 years. The fair value of the warrants at issuance was initially recorded as a liability with the residual amount of proceeds allocated to share capital.

	On February 29, 2012, the Company completed a private placement offering of 1,848,601 units at a price of $2.20 (C$2.20) each for total gross proceeds, before expenses, of $4,069,547. Each unit consists of one common share and one half of one common share purchase warrant. Each whole warrant entitles the holder to acquire one common share at a price of C$2.60. The warrants expire on February 28, 2017. After paying brokerage fees and other unit issue costs, the offering generated net cash of $3,843,995. The total unit issuance cost of $225,551 has been allocated, on a pro-rata basis, as $178,521 to the shares and $47,030 to the warrants and recorded, respectively, to share capital and warrant issuance costs in the consolidated statement of operations and comprehensive income (loss).

	On the date of issuance, the Black-Scholes aggregate value of the 924,302 warrants was $850,907 based on an assumed risk-free interest rate of 1.44%, volatility of 40%, a zero dividend yield and an expected life of 5 years. The fair value of the warrants at issuance was initially recorded as a liability with the residual amount of proceeds from the private placement being allocated to share capital.

	On October 22, 2013, the Company announced that it had completed an underwritten public offering of 3,750,000 common shares, at a price of $8.00 per share, representing gross proceeds of $30,000,000. On November 1, 2013, the offering’s underwriter completed the exercise of its over-allotment option to purchase a further 562,500 shares at $8.00 bringing the aggregate financing gross proceeds to $34,500,000. The cost of the financing, including commissions and professional fees, was $2,461,683, resulting in net proceeds of $32,038,317.

	(b) Authorized share capital

	The Company’s authorized share capital consists of an unlimited number of common and preferred shares without par value.

	(c) Warrants to purchase common shares

	During the year ended December 31, 2013, there were 105,683 warrants exercised for $288,823 in cash (December 31, 2012 – 230,841 warrants for $632,282) and 468,000 warrants exercised using the cashless exercise provision in return for 199,765 common shares (December 31, 2012 – 54,545 warrants for 38,644 common shares).

	A following table summarizes the Company’s warrant activity for the years ended December 31, 2012 and 2013:

			Common shares				Weighted average				Weighted				Range of					Range of			Weighted		Aggregate		Aggregate
			purchasable upon				exercise price (C$)				average exercise				exercise prices					exercise prices			average		intrinsic value		intrinsic value
			exercise of								price (US$)				(C$)					(US$)			remaining		(C$)		(US$)
			warrants																				contractual life
																							(years)

	Balance, December 31, 2011			949,495			$	3.25			$	3.2			$1.65	-	$3.35			$1.62	-	$3.29		4.6	$	-	$	-
	Issued			924,302			$	2.6			$	2.61				$2.60					$2.61
	Exercised			(285,386	)		$	2.53			$	2.54			$1.65	-	$3.35			$1.66	-	$3.37
	Balance, December 31, 2012			1,588,411			$	3			$	3.02			$2.50	-	$3.35			$2.51	-	$3.37		3.8		3,140,893		3,156,912
	Issued			-				-				-				-					-
	Exercised			(573,683	)		$	3.19			$	3			$2.60	-	$3.35			$2.44	-	$3.15						-
	Balance, December 31, 2013			1,014,728			$	2.9			$	2.72			$2.60	-	$3.35			$2.44	-	$3.15		2.7	$	5,635,446	$	5,298,447

	The aggregate intrinsic value in the table above is calculated based on the difference between the exercise price of the warrants and the quoted price of the Company’s common stock as of the reporting date.

	All of the Company’s warrants were exercisable as of December 31, 2013.

	The weighted average Black-Scholes option-pricing assumptions and the resultant fair values are as follows for warrants outstanding at December 31, 2013 and 2012 are as follows:

			Year ended December 31
			2013				2012

	Dividend yield			0	%			0	%
	Expected volatility			47.03	%			40	%
	Risk-free interest rate			1.13	%			1.28	%
	Expected average term (years)		1.6				3.8
	Fair value of warrants outstanding		$	5.3			$	2.51
	Aggregate fair value of warrants outstanding		$	5,378,722			$	4,014,821

	The value of the Company’s warrants is particularly sensitive to changes in the Company’s share price and the estimated rate of share price volatility. Based on changes in the Company’s business and general stock market conditions since the warrants were issued in 2011 and 2012, in 2013, the Company undertook a review of its warrant fair value assumptions. The previous assumption for warrant expected life was the warrant’s remaining contractual term. Based on the pattern of exercises of the warrants the Company has now reduced the expected life to a weighted average of 1.6 years as of December 31, 2013. The previous assumption for expected volatility in respect of the warrants was 40%. The Company is now calculating volatility based on historic share price fluctuations, which, at December 31, 2013, gave a weighted average expected volatility of 47.03%. The reduction in expected life has the effect of reducing the fair value of the warrants, whereas, the increase in expected volatility increases the fair value of the warrants.

	(e) Stock-based compensation

	The Company has three share-based compensation plans; the “2007 Plan”, the “2011 Plan” and the “Protiva Option Plan”.

	On June 22, 2011, the shareholders of the Company approved an omnibus stock-based compensation plan (the “2011 Plan”) and a 273,889 increase in the number of stock-based compensation awards that the Company is permitted to issue. The Company’s pre-existing 2007 Plan was limited to the granting of stock options as equity incentive awards whereas the 2011 Plan also allows for the issuance of tandem stock appreciation rights, restricted stock units and deferred stock units (collectively, and including options, referred to as “Awards”). The 2011 Plan replaces the 2007 Plan. The 2007 Plan will continue to govern the options granted thereunder. No further options will be granted under the Company’s 2007 Plan.

Under the Company’s 2007 Plan the Board of Directors granted options to employees, directors and consultants of the Company. The exercise price of the options was determined by the Company’s Board of Directors but was always at least equal to the closing market price of the common shares on the day preceding the date of grant and the term of options granted did not exceed 10 years. The options granted generally vested over three years for employees and immediately for directors.

Under the Company’s 2011 Plan the Board of Directors may grant options, and other types of Awards, to employees, directors and consultants of the Company. The exercise price of the options is determined by the Company’s Board of Directors but will be at least equal to the closing market price of the common shares on the day preceding the date of grant and the term may not exceed 10 years. Options granted generally vest over three years for employees and immediately for directors.

Hereafter, information on options governed by the 2007 Plan and 2011 Plan is presented on a consolidated basis as the terms of the two plans are similar. Information on the Protiva Option Plan is presented separately.

On June 20, 2012, the shareholders of the Company approved a 550,726 increase in the number of stock-based compensation awards that the Company is permitted to issue.

Stock option activity for the Company’s 2007 Plan and 2011 Plan

		Number of				Weighted				Weighted				Aggregate				Aggregate
		optioned				average exercise				average exercise				intrinsic				intrinsic
		common shares				price (C$)				price (US$)				value (C$)				value (US$)

Balance, December 31, 2010			1,083,432			$	7.95			$	7.72			$	756,628			$	734,881
Options granted			403,100			$	2.14			$	2.17
Options exercised			(1,667	)		$	1.5			$	1.52			$	1,330			$	1,346
Options forfeited, cancelled or expired			(71,547	)		$	27.42			$	27.74
Balance, December 31, 2011			1,413,318			$	5.32			$	5.38			$	1,800			$	1,821
Options granted			326,300			$	4.16			$	4.16
Options exercised			(28,417	)		$	2.34			$	2.34			$	81,545			$	81,598
Options forfeited, cancelled or expired			(62,355	)		$	21.27			$	21.29
Balance, December 31, 2012			1,648,846			$	4.54			$	4.54			$	2,299,512			$	2,300,996
Options granted			270,250			$	7.52			$	7.3
Options exercised			(124,246	)		$	3.22			$	3.13			$	551,385			$	535,369
Options forfeited, cancelled or expired			(64,085	)		$	21.87			$	21.23
Balance, December 31, 2013			1,730,765			$	4.45			$	4.32			$	7,029,795			$	6,825,608

Options under the 2007 Plan and 2011 Plan expire at various dates from December 14, 2014 to December 5, 2023.

The following table summarizes information pertaining to stock options outstanding at December 31, 2013 under the Company’s 2007 Plan and 2011 Plan:

					Options outstanding December 31, 2013																Options exercisable December 31, 2013
Range of					Number				Weighted				Weighted				Weighted				Number		Weighted		Weighted
Exercise prices					of options				average				average				average				of options		average		average
					outstanding				remaining				exercise				exercise				exercisable		exercise		exercise
									contractual				price (C$)				price (US$)						price (C$)		price (US$)
									life (years)

$1.50	to	$1.90				261,475				6.7			$	1.71			$	1.66				236,475	$	1.71	$	1.66
$2.10	to	$2.60				279,000				7.7			$	2.32			$	2.25				236,175	$	2.35	$	2.28
$3.00	to	$3.10				108,979				2.2			$	3.04			$	2.95				108,979	$	3.04	$	2.95
$3.73	to	$3.85				153,250				6.1			$	3.84			$	3.73				150,650	$	3.85	$	3.74
$4.38	to	$4.54				21,250				9.2			$	4.53			$	4.4				5,313	$	4.53	$	4.4
$4.65	to	$5.60				576,846				6.2			$	5.25			$	5.1				474,909	$	5.27	$	5.12
$5.69	to	$11.60				329,965				7.6			$	7.79			$	7.56				164,590	$	7.45	$	7.23
$1.50	to	$11.60				1,730,765				6.6			$	4.45			$	4.32				1,377,091	$	4.08	$	3.96

At December 31, 2013, there were 1,377,091 options exercisable (December 31, 2012 – 1,315,155; December 31, 2011 - 1,015,224) with a weighted average exercise price of $3.96 (C$4.08). The weighted average remaining contractual life of exercisable options as at December 31, 2013 was 5.9 years. The aggregate intrinsic value of options exercisable at December 31, 2013 was $5,869,668.

A summary of the Company’s non-vested stock option activity and related information for the year ended December 31, 2013 is as follows:

		Number of				Weighted				Weighted
		optioned				average				average
		common shares				fair value (C$)				fair value (US$)

Non-vested at December 31, 2012			333,691			$	3.38			$	3.38

Options granted			270,250			$	7.52				7.3
Options vested			(219,966	)		$	4.47				4.34
Non-vested options forfeited			(30,300	)		$	3.74				3.63
Non-vested at December 31, 2013			353,675			$	5.44			$	5.28

The weighted average remaining contractual life for options expected to vest at December 31, 2013 was 9.2 years and the weighted average exercise price for these options was $5.73 (C$5.90) per share.

The aggregate intrinsic value of options expected to vest as at December 31, 2013 was $942,918 (December 31, 2012 - $450,620; December 31, 2011 - $nil).

The total fair value of options that vested during the year ended December 31, 2013 was $954,534 (2012 - $1,071,240; 2011 - $355,657).

Valuation assumptions for the Company’s 2007 Plan and 2011 Plan

The fair value of stock options at date of grant, based on the following assumptions, was estimated using the Black-Scholes option-pricing model. Assumptions on the dividend yield are based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends. Assumptions about the Company’s expected stock-price volatility are based on the historical volatility of the Company’s publicly traded stock. The risk-free interest rate used for each grant is equal to the zero coupon rate for instruments with a similar expected life. Expected life assumptions are based on the Company’s historical data. The Company currently expects, based on an analysis of its historical forfeitures, that approximately 98% of its options issued will ultimately vest, and has applied a forfeiture rate of 2.0% to all unvested options held as of December 31, 2013. The Company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeitures are higher than estimated. The weighted average option pricing assumptions and the resultant fair values are as follows:

		Year ended December 31
		2013				2012				2011

Dividend yield			0	%			0	%			0	%
Expected volatility			111.61	%			120.4	%			116.26	%
Risk-free interest rate			2.39	%			1.56	%			2.51	%
Expected average option term (years)			9.6				8.2				9.6
Fair value of options granted (C$)		$	6.96			$	3.83			$	2

Stock-based compensation expense for the Company’s 2007 Plan and 2011 Plan

An expense for stock-based compensation for options awarded to employees and calculated in accordance with the fair value method has been recorded in the consolidated statement of operations and comprehensive income (loss) as follows:

		Year ended December 31
		2013				2012				2011

Research, development, collaborations and contracts expenses		$	621,807			$	772,367			$	500,425
General and administrative expenses			281,198				209,923				133,024
Total		$	903,005			$	982,290			$	633,449

At December 31, 2013, there remains $1,619,451 of unearned compensation expense related to unvested employee stock options to be recognized as expense over a weighted-average period of approximately 15 months.

Protiva Option Plan

On May 30, 2008, as a condition of the acquisition of Protiva Biotherapeutics Inc., a total of 350,457 common shares of the Company were reserved for the exercise of 519,073 Protiva share options (“Protiva Options”). The Protiva Options have an exercise price of C$0.30, were fully vested and exercisable as of May 30, 2008, expire at various dates from February 4, 2014 to March 1, 2018 and upon exercise each option will be converted into approximately 0.6752 shares of the Company (the same ratio at which Protiva common shares were exchanged for Company common shares at completion of the acquisition of Protiva). The Protiva Options are not part of the Company’s 2007 Plan or 2011 Plan and the Company is not permitted to grant any further Protiva Options.

The following table sets forth outstanding options under the Protiva Option Plan:

		Number of Protiva				Equivalent number				Weighted				Weighted
		Options				of Company				average exercise				average
						common shares				price (C$)				exercise price
														(US$)

Balance, December 31, 2010			518,223				349,883				0.3				0.3
Options exercised			(27,202	)			(18,366	)			0.3				0.3
Options forfeited, cancelled or expired			-				-				-				-
Balance, December 31, 2011			491,020				331,517				0.3				0.3
Options exercised			(15,135	)			(10,218	)			0.3				0.3
Options forfeited, cancelled or expired			-				-				-				-
Balance, December 31, 2012			475,885				321,299			$	0.3			$	0.3
Options exercised			(2,000	)			(1,350	)			0.3				0.29
Options forfeited, cancelled or expired			(1,000	)			(675	)			0.3				0.29
Balance, December 31, 2013			472,885				319,274				0.3				0.29

The weighted average remaining contractual life of exercisable Protiva Options as at December 31, 2013 was 2.1 years.

The aggregate intrinsic value of Protiva Options outstanding at December 31, 2013 was $3,866,368. The intrinsic value of Protiva Options exercised in the year ended December 31, 2013 was $8,265 (2012 - $18,941; 2011 - $43,114).

Awards outstanding and available for issuance

Combining all of the Company’s share-based compensation plans, at December 31, 2013, the Company has 2,050,039 options outstanding and a further 216,523 Awards available for issuance.

Note_6_Government_Grants_and_R

Note 6 - Government Grants and Refundable Investment Tax Credits	12 Months Ended
	Dec. 31, 2013
Government Grants And Refundable Investment Tax Credits [Abstract]	'
Government Grants And Refundable Investment Tax Credits [Text Block]	'
	6. Government grants and refundable investment tax credits

	Government grants and refundable investment tax credits have been recorded as a reduction in research and development expenses.

	Government grants for the year ended December 31, 2013 include $68,633 in funding from the U.S. National Institutes of Health (2012 - $274,254; 2011 - $344,744).

	The Company’s estimated claim for refundable Scientific Research and Experimental Development investment tax credits for the year ended December 31, 2013 is $42,804 (2012 - $nil; 2011 - $21,150).

Note_7_Income_Taxes

Note 7 - Income Taxes	12 Months Ended
Note 7 - Income Taxes	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	7. Income taxes

	Income tax (recovery) expense varies from the amounts that would be computed by applying the combined Canadian federal and provincial income tax rate of 17.7% (year ended December 31, 2012 – 17.5%; December 31, 2011 – 26.5%) to the loss before income taxes as shown in the following tables:

		Year ended December 31
		2013			2012			2011

	Computed taxes (recoveries) at Canadian federal and provincial tax rates	$	(2,380,267	)	$	7,486,268		$	(2,589,310	)
	Differences due to change in enacted tax rates		(5,723	)		780,963			700,342
	Difference due to change in tax rate on opening deferred taxes		-			2,636,377			3,369,825
	Permanent and other differences		1,820,842			2,202,291			141,587
	Change in valuation allowance		565,147			(2,515,765	)		(1,622,445	)
	Utilization of investment tax credits		-			(10,590,133	)		-
	Income tax (recovery) expense	$	-		$	-		$	-

	As at December 31, 2013, the Company has investment tax credits available to reduce Canadian federal income taxes of $6,859,352 (December 31, 2012 - $5,891,094) and provincial income taxes of $2,431,691 (December 31, 2012 - $1,914,623) and expiring between 2014 and 2033.

	At December 31, 2013, the Company has scientific research and experimental development expenditures of $49,906,852 (December 31, 2012 - $48,357,146) available for indefinite carry-forward and $24,526,593 (December 31, 2012 - $21,457,451) of net operating losses due to expire between 2028 and 2033 and which can be used to offset future taxable income in Canada.

	On November 23, 2011, the Company was registered as a corporation under the Business Activity Act in the province of British Columbia. Under this program, provincial corporation tax charged on foreign income earned from the Company’s patents will be eligible for a 75% tax refund up to a maximum of C$8,000,000. Significant components of the Company’s deferred tax assets are shown below:

		Year ended December 31
		2013			2012

	Deferred tax assets:
	Non-capital loss carryforwards	$	4,354,066		$	4,561,144
	Research and development deductions		8,858,564			8,583,554
	Book amortization in excess of tax		2,170,922			1,934,818
	Share issue costs		(136,329	)		(26,133	)
	Revenue recognized for tax purposes in excess of revenue recognized for accounting purposes		667,542			-
	Tax value in excess of accounting value in lease inducements		(2,821	)		8,041
	Accounting value in excess of tax value in intangible assets		-			372,892
	Provincial investment tax credits		392,063			304,545
	Total deferred tax assets		16,304,008			15,738,861
	Valuation allowance		(16,304,008	)		(15,738,861	)
	Net deferred tax assets	$	-		$	-

Note_8_Contingencies_and_Commi

Note 8 - Contingencies and Commitments	12 Months Ended
Note 8 - Contingencies and Commitments	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	8. Contingencies and commitments

	Property lease

	Effective July 29, 2009 the Company signed an amendment to the operating lease for its laboratory and office premises. The amended lease expires in July 2014 but the Company has the option to extend the lease to 2017 and then to 2022 and then to 2027. The amended lease included a signing incentive payment. In accordance with the Company’s accounting policy the signing incentive payment is being amortized on a straight-line basis over the term of the amended lease.

	The minimum commitment for rent and estimated operating costs for the year ended December 31, 2014 is $705,150.

	The Company’s lease expense, for the year ended December 31, 2013 of $1,224,794 has been recorded in the consolidated statements of operations and comprehensive income (loss) (2012 - $937,365; 2011 - $944,457).

	The Company has netted $nil of sub-lease income against lease expense in the year ended December 31, 2013 (2012 - $172,034; 2011 - $196,555).

	Product development partnership with the Canadian Government

	The Company entered into a Technology Partnerships Canada ("TPC") agreement with the Canadian Federal Government on November 12, 1999. Under this agreement, TPC agreed to fund 27% of the costs incurred by the Company, prior to March 31, 2004, in the development of certain oligonucleotide product candidates up to a maximum contribution from TPC of $7,179,170 (C$9,329,912). As at December 31, 2013, a cumulative contribution of $3,480,217 (C$3,701,571) has been received and the Company does not expect any further funding under this agreement. In return for the funding provided by TPC, the Company agreed to pay royalties on the share of future licensing and product revenue, if any, that is received by the Company on certain non-siRNA oligonucleotide product candidates covered by the funding under the agreement. These royalties are payable until a certain cumulative payment amount is achieved or until a pre-specified date. In addition, until a cumulative amount equal to the funding actually received under the agreement has been paid to TPC, the Company agreed to pay 2.5% royalties on any royalties the Company receives for Marqibo. For the year-ended December 31, 2013, the Company earned royalties on Marqibo sales in the amount of $39,581 (see note 3(e)), resulting in $990 recorded by the Company as royalty payable to TPC.

	Contingently payable promissory notes

	On March 25, 2008, Protiva declared dividends totaling $12,000,000. The dividends were paid by Protiva issuing promissory notes on May 23, 2008. Recourse against Protiva for payment of the promissory notes will be limited to Protiva’s receipt, if any, of up to $12,000,000 in license payments from Merck (see note 3(f)). Protiva will pay these funds if and when it receives them, to the former Protiva shareholders in satisfaction of the promissory notes. As contingent items the $12,000,000 receivable and the related promissory notes payable are not recorded in the Company’s consolidated balance sheet.

	License and collaboration agreement with Halo-Bio RNAi Therapeutics, Inc. (“Halo-Bio”)

	On August 24, 2011, the Company entered into a license and collaboration agreement with Halo-Bio. Under the agreement, Halo-Bio granted the Company an exclusive license to its multivalent ribonucleic acid (“MV-RNA”) technology. The agreement provides for the companies to work together to design and develop MV-RNA molecules to gene targets of interest to the Company and to combine MV-RNA molecules with the Company’s LNP technology to develop therapeutic products.

	The Company paid Halo-Bio an initial license fee of $100,000 and recorded this amount as a research, development, collaborations and contracts expense in the year ended December 31, 2011.

	The agreement was amended on August 8, 2012 to adjust the future license fees and other contingent payments. The Company recorded a further $450,000 in license fees to research, development, collaborations and contracts expense in the year ended December 31, 2012, in respect of the agreement.

	The Company terminated the agreement with Halo-Bio on July 31, 2013. There are no further payments due or contingently payable to Halo-Bio.

	License agreement with Marina Biotech, Inc. (“Marina”)

	On November 29, 2012 the Company announced a worldwide, non-exclusive license to a novel RNAi payload technology called Unlocked Nucleobase Analog (“UNA”) from Marina for the development of RNAi therapeutics.

	UNA technology can be used in the development of RNAi therapeutics, which treat disease by silencing specific disease causing genes. UNAs can be incorporated into RNAi drugs and have the potential to improve them by increasing their stability and reducing off-target effects.

	Under the license agreement the Company paid Marina an upfront fee of $300,000. A further license payment of $200,000 was paid in 2013 and the Company will make milestone payments of up to $3,250,000 and royalties on each product developed by the Company that uses Marina’s UNA technology. The payments to Marina are expensed to research, development, collaborations and contracts expense.

	Effective August 9, 2013, Marina’s UNA technology was acquired by Arcturus Therapeutics, Inc. (“Arcturus”) and the UNA license agreement between the Company and Marina was assigned to Arcturus. The terms of the license are otherwise unchanged.

	The Company believes that it is probable they will use Arcturus’s UNA technology for one of its product candidates in the foreseeable future.

Note_9_Concentrations_of_Busin

Note 9 - Concentrations of Business Risk	12 Months Ended
	Dec. 31, 2013
Risks and Uncertainties [Abstract]	'
Concentration Risk Disclosure [Text Block]	'
	9. Concentrations of business risk

	Credit risk

	Credit risk is defined by the Company as an unexpected loss in cash and earnings if a collaborative partner is unable to pay its obligations in due time. The Company’s main source of credit risk is related to its accounts receivable balance which principally represents temporary financing provided to collaborative partners in the normal course of operations.

	The Company does not currently maintain a provision for bad debts as the majority of accounts receivable are from collaborative partners or government agencies and are considered low risk.

	The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at December 31, 2013 was the accounts receivable balance of $116,556 (December 31, 2012 - $1,074,891).

	All accounts receivable balances were current as at December 31, 2013 and December 31, 2012.

	Significant collaborators and customers risk

	We depend on a small number of collaborators and customers for a significant portion of our revenues (see note 3).

	Liquidity Risk

	Liquidity risk results from the Company’s potential inability to meet its financial liabilities, for example payments to suppliers. The Company ensures sufficient liquidity through the management of net working capital and cash balances.

	The Company’s liquidity risk is primarily attributable to its cash and cash equivalents. The Company limits exposure to liquidity risk on its liquid assets through maintaining its cash and cash equivalent deposits with high-credit quality financial institutions. Due to the nature of these investments, the funds are available on demand to provide optimal financial flexibility.

	The Company believes that its current sources of liquidity are sufficient to cover its likely applicable short term cash obligations. The Company’s financial obligations include accounts payable and accrued liabilities which generally fall due within 45 days.

	The net liquidity of the Company is considered to be the cash and cash equivalents less accounts payable and accrued liabilities

		31-Dec-13			31-Dec-12
	Cash, cash equivalents and short term investments	$	68,716,531		$	47,024,124
	Less: Accounts payable and accrued liabilities		(3,680,462	)		(3,795,546	)
		$	65,036,069		$	43,228,578

	Foreign currency risk

	For the year-ended December 31, 2013, the Company has converted its reporting currency to the US dollar, and the Company’s functional currency remains as the Canadian dollar (note 2). The results of the Company’s operations are subject to currency transaction and translation risk as the Company’s revenues and expenses are denominated in both Canadian and US dollars. The fluctuation of the US dollar in relation to the Canadian dollar will consequently have an impact upon the Company’s income or loss and may also affect the value of the Company’s assets, liabilities, and the amount of shareholders’ equity both as recorded in the Company’s financial statements, in the Canadian functional currency, and as reported, for presentation purposes, in the US dollar.

	The Company manages its US dollar exchange rate risk by, whenever possible, using cash received from US dollar revenues and financing to pay US dollar expenses. Prior to the financing in October 2013 (note 5(a)), which was denominated in US dollars, the Company’s policy was to convert all but a working capital level of US dollars into Canadian dollars. Given the Company’s increasing level of US dollar expenses, the Company maintained the funds raised in October 2013 in US dollars in order to achieve a natural foreign exchange hedge.

	In November 2012, the Company used a forward exchange contract to convert US$45,000,000 into Canadian dollars. The Company has not entered into any other agreements or purchased any instruments to hedge possible currency risks. The Company’s exposure to US dollar currency expressed in Canadian dollars was as follows:

	(in C$)	31-Dec-13			31-Dec-12
	Cash and cash equivalents	$	38,900,944		$	149,058
	Accounts receivable		10,840			1,025,306
	Accrued revenue		225,892			2,361,836
	Accounts payable and accrued liabilities		(1,889,480	)		(2,969,454	)
		$	37,248,196		$	566,746

	An analysis of the Company’s sensitivity to foreign currency exchange rate movements is not provided in these financial statements as the Company’s US dollar cash holdings and expected US dollar revenues are sufficient to cover US dollar expenses for the foreseeable future.

Note_10_Supplementary_Informat

Note 10 - Supplementary Information	12 Months Ended
Note 10 - Supplementary Information	Dec. 31, 2013
Disclosure Text Block Supplement [Abstract]	'
Supplemental Balance Sheet Disclosures [Text Block]	'
	10. Supplementary information

	Accounts payable and accrued liabilities is comprised of the following:

		31-Dec-13		31-Dec-12

	Trade accounts payable	$	1,217,242	$	805,790
	Research and development accruals		1,404,905		310,492
	License fee accruals		-		1,649,957
	Professional fee accruals		247,148		602,113
	Deferred lease inducements		16,454		48,078
	Other accrued liabilities		794,713		379,116
		$	3,680,462	$	3,795,546

Note_11_Subsequent_Events

Note 11 - Subsequent Events	12 Months Ended
Note 11 - Subsequent Events	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	11. Subsequent events

	Option and Services Agreements with Monsanto Company (“Monsanto”)

	On January 13, 2014, the Company and Monsanto signed an Option Agreement and a Services Agreement (together, the “Agreements”). Under the Agreements, Monsanto may obtain a license to use the Company’s proprietary delivery technology and related intellectual property for use in agriculture. Over the option period, which is expected to be approximately four years, the Company will provide lipid formulations for Monsanto’s research and development activities, and Monsanto will make certain payments to the Company to maintain its option rights. The maximum potential value of the transaction is $86,200,000 following the successful completion of milestones. In January 2014, the Company received $14,500,000 of the $16,500,000 near term payments as outlined in the terms of the Agreements.

	At any time during the option period, Monsanto may choose to exercise its option, in which case Monsanto would pay the Company an option exercise fee and would receive a worldwide, exclusive right to use the Company’s proprietary delivery technology in the field of agriculture. Monsanto may elect to terminate this option at their discretion. The Company retains all rights to therapeutics uses of all current intellectual property and intellectual property developed under the Agreements.

	Base shelf prospectus

	On February 28, 2014, the Company filed a short form base shelf prospectus with securities regulatory authorities in Canada, other than Quebec, and a corresponding shelf registration statement with the United States Securities and Exchange Commission on Form F-10.

	The base shelf registration statement provides for the potential of offering, in Canada and the United States, up to $150,000,000 of Tekmira’s common shares, warrants to purchase common shares and/or units comprising any combination of the foregoing from time to time over the next 25 months.

Note_12_Interim_Financial_Data

Note 12 - Interim Financial Data (unaudited)	12 Months Ended
Note 12 - Interim Financial Data (unaudited)	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Information [Text Block]	'
	12. Interim financial data (unaudited)

			2013
			Q1			Q2			Q3			Q4		Total

	Revenue		2,131,519			2,843,806			2,962,809			7,526,016			15,464,150

	Loss from operations		(2,993,811	)		(3,070,968	)		(3,652,191	)		(2,436,248	)		(12,153,218	)

	Net loss		(2,546,244	)		(3,014,928	)		(5,905,923	)		(2,597,131	)		(14,064,226	)

	Basic and diluted net loss per share	$	(0.18	)	$	(0.21	)	$	(0.41	)	$	(0.15	)	$	(0.92	)

			2012
			Q1			Q2			Q3			Q4		Total

	Revenue		3,586,970			3,643,296			3,067,593			3,807,327			14,105,186

	Loss from operations		(2,651,931	)		(2,599,027	)		(1,784,666	)		(5,908,924	)		(12,944,548	)

	Net (loss) income		(3,180,259	)		(1,935,761	)		(3,457,600	)		38,185,616			29,611,996

	Basic net (loss) income per share	$	(0.25	)	$	(0.14	)	$	(0.25	)	$	2.72		$	2.16

	Diluted net (loss) income per share	$	(0.25	)	$	(0.14	)	$	(0.25	)	$	2.51		$	2.07

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
Accounting Policies, by Policy (Policies)	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of presentation

	Tekmira Pharmaceuticals Corporation was incorporated on October 6, 2005 as an inactive wholly owned subsidiary of Inex Pharmaceuticals Corporation (“Inex”). Pursuant to a “Plan of Arrangement” effective April 30, 2007 the business and substantially all of the assets and liabilities of Inex were transferred to the Company. The consolidated financial statements for all periods presented herein include the consolidated operations of Inex until April 30, 2007 and the operations of the Company thereafter.

	These consolidated financial statements include the accounts of the Company and its two wholly-owned subsidiaries, Protiva Biotherapeutics Inc. and Protiva Biotherapeutics (USA), Inc., which were acquired on May 30, 2008. All intercompany transactions and balances have been eliminated on consolidation
Use of Estimates, Policy [Policy Text Block]	'
	Use of estimates

	The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, revenue, expenses, contingent assets and contingent liabilities as at the end or during the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring the use of management estimates relate to recognition of revenue, stock-based compensation, share purchase warrant valuation and the amounts recorded as accrued liabilities.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and cash equivalents

	Cash and cash equivalents are all highly liquid instruments with an original maturity of three months or less when purchased. Cash equivalents are recorded at cost plus accrued interest. The carrying value of these cash equivalents approximates their fair value.
Fair Value Measurement, Policy [Policy Text Block]	'
	Fair value of financial instruments

	We measure certain financial instruments and other items at fair value.

	To determine the fair value, we use the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:

		•		Level 1 inputs are quoted market prices for identical instruments available in active markets.

		•		Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.

		•		Level 3 inputs are unobservable inputs for the asset or liability and will reflect management’s assumptions about market assumptions that would be used to price the asset or liability.

	Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.

	The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, investment tax credits receivable, accounts payable and accrued liabilities, and warrants and promissory notes.

	The carrying values of cash and cash equivalents are recorded at fair value based on quoted prices in active markets. The carrying values of accounts receivable, investment tax credits receivable and accounts payable and accrued liabilities approximate their fair values due to the immediate or short-term maturity of these financial instruments.

	As quoted prices for the warrants are not readily available, the Company has used a Black-Scholes pricing model, as described in Note 5, to estimate fair value. These are level 3 inputs as defined above.

	The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:

			Level 1			Level 2		Level 3			31-Dec-13
	Assets
	Cash		$	68,716,531			-		-		$	68,716,531
	Guaranteed Investment Certificates			-			-		-			-
	Total		$	68,716,531			-		-		$	68,716,531

	Liabilities
	Warrants		$	-			-	$	5,378,772		$	5,378,772

			Level 1			Level 2		Level 3			31-Dec-12
	Assets
	Cash		$	44,373,720			-		-		$	44,373,720
	Guaranteed Investment Certificates			2,650,404			-		-			2,650,404
	Total		$	47,024,124			-		-		$	47,024,124

	Liabilities
	Warrants		$	-			-	$	4,014,821		$	4,014,821

	The following table presents the changes in fair value of the Company’s warrants:

			Liability at			Opening		Fair value of			Increase			Foreign			Liability
			beginning			liability of		warrants			(decrease) in			exchange			at end
			of the year			warrants issued in		exercised			value of			(gain) loss			of the year
						the year		in the			warrants
								year

	Year ended December 31, 2011		$	-		$	786,919	$	-		$	(579,474	)	$	(5,825	)	$	201,620
	Year ended December 31, 2012		$	201,620		$	850,907	$	(880,691	)	$	3,821,635		$	21,350		$	4,014,821
	Year ended December 31, 2013		$	4,014,821		$	-	$	(1,854,028	)	$	3,530,314		$	(312,335	)	$	5,378,772
Inventory, Policy [Policy Text Block]	'
	Inventory

	Inventory includes materials assigned for the manufacture of products for collaborative partners and manufacturing costs for products awaiting acceptance by collaborative partners. Inventory is carried at the lower of cost and net realizable value. The cost of inventories includes all costs of purchase, costs of manufacturing and other costs incurred in bringing the inventories to their present location and condition.

	Materials purchased for the Company’s own research and development products, or, for collaborative partners where an acceptance criteria does not apply, are not recorded as inventory but are expensed at the time of receipt.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and equipment

	Property and equipment is recorded at cost less impairment losses, accumulated depreciation, related government grants and investment tax credits. The Company records depreciation using the straight-line method over the estimated useful lives of the capital assets as follows:

		Rate

	Laboratory equipment (years)		5
	Computer and office equipment (years)	2	-	5
	Furniture and fixtures (years)		5

	Leasehold improvements are depreciated over their estimated useful lives but in no case longer than the lease term, except where lease renewal is reasonably assured. Assets held under capital leases that do not allow for ownership to pass to the Company are depreciated using the straight-line method over their useful life, not exceeding the lease term. Assets under construction are not depreciated until usage has begun.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	'
	Intangible assets

	The costs incurred in establishing and maintaining patents for intellectual property developed internally are expensed in the period incurred
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	'
	Impairment of long-lived assets

	If there is a major event indicating that the carrying value of property and equipment may be impaired then management will perform an impairment test and if the recoverable value, based on undiscounted future cash flows, exceeds carrying value then such assets are written down to their fair values
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue recognition

	The Company earns revenue from research and development collaboration and contract services, licensing fees and milestone payments. Revenues associated with multiple element arrangements are attributed to the various elements based on their relative fair values or are recognized as a single unit of accounting when relative fair values are not determinable. Non-refundable payments received under collaborative research and development agreements are recorded as revenue as services are performed and related expenditures are incurred. Non-refundable upfront license fees from collaborative licensing and development arrangements are recognized as the Company fulfills its obligations related to the various elements within the agreements, in accordance with the contractual arrangements with third parties and the term over which the underlying benefit is being conferred. Revenue earned under contractual arrangements upon the occurrence of specified milestones is recognized as the milestones are achieved and collection is reasonably assured.

	Revenue earned under research and development manufacturing collaborations where the Company bears some or all of the risk of a product manufacturing failure is recognized when the purchaser accepts the product and there are no remaining rights of return.

	Revenue earned under research and development collaborations where the Company does not bear any risk of product manufacturing failure is recognized in the period the work is performed. For contracts where the manufacturing amount is specified, revenue is recognized as product is manufactured in proportion to the total amount specified under the contract.

	Revenue and expenses under the contract with the United States Government Department of Defense (“DoD”) are being recorded using the percentage-of-completion method. Contract progress is based on costs incurred to date. Expenses under the contract are recorded in the Company’s consolidated statement of operations and comprehensive income (loss) as they are incurred. Government contract revenues related to expenses incurred under the contract are recorded in the same period as those expenses. Expenses accrued under the contract but not yet invoiced are recorded in the Company’s balance sheet as accrued liabilities and accrued revenues. Equipment purchased under the contract is recorded on the Company’s balance sheet as deferred expense and deferred revenue and amortized, on a straight-line basis, over the life of the contract.

	Cash or other compensation received in advance of meeting the revenue recognition criteria is recorded on the balance sheet as deferred revenue. Revenue meeting recognition criteria but not yet received or receivable is recorded on the balance sheet as accrued revenue.
Lease, Policy [Policy Text Block]	'
	Leases and lease inducements

	Leases entered into are classified as either capital or operating leases. Leases which substantially transfer all benefits and risks of ownership of property to the Company are accounted for as capital leases. At the time a capital lease is entered into, an asset is recorded together with its related long-term obligation to reflect the purchase and financing.

	All other leases are accounted for as operating leases wherein rental payments are expensed as incurred.

	Lease inducements represent leasehold improvement allowances and reduced or free rent periods and are amortized on a straight-line basis over the term of the lease and are recorded as a reduction of rent expense
Research, Development, and Computer Software, Policy [Policy Text Block]	'
	Research and development costs

	Research and development costs, including acquired in-process research and development expenses for which there is no alternative future use, are charged as an expense in the period in which they are incurred.
Earnings Per Share, Policy [Policy Text Block]	'
	Income or loss per share

	Income or loss per share is calculated based on the weighted average number of common shares outstanding. Diluted loss per share does not differ from basic loss per share since the effect of the Company’s stock options and warrants is anti-dilutive. Diluted income per share is calculated using the treasury stock method which uses the weighted average number of common shares outstanding during the period and also includes the dilutive effect of potentially issuable common shares from outstanding, in-the-money stock options and warrants.

	The following table sets out the computation of basic and diluted net income (loss) per common share:

			Year ended December 31
			2013			2012		2011
	Numerator:
	Net income (loss)		$	(14,064,226	)	$	29,611,996	$	(10,083,491	)
	Denominator:
	Weighted average number of common shares			15,302,680			13,727,925		11,318,766
	Effect of dilutive securities:
	Warrants			-			177,374		-
	Options			-			415,515		-
	Diluted weighted average number of common shares			15,302,680			14,320,814		11,318,766

	Basic income (loss) per common share		$	(0.92	)	$	2.16	$	(0.89	)

	Diluted income (loss) per common share		$	(0.92	)	$	2.07	$	(0.89	)

	For the year ended December 31, 2013, potential common shares of 3,064,767 were excluded from the calculation of income per common share because their inclusion would be anti-dilutive (December 31, 2012 –1,085,503; December 31, 2011 – 2,694,330).
Government Grants And Refundable Intestment Tax Credits [Policy Text Block]	'
	Government grants and refundable investment tax credits

	Government grants and tax credits provided for current expenses is included in the determination of income or loss for the year, as a reduction of the expenses to which it relates. Government grants and tax credits towards the acquisition of property and equipment is deducted from the cost of the related property and equipment.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	'
	Foreign currency translation and change in reporting currency

	The functional currency of the Company is the Canadian dollar. For the Company and its integrated subsidiaries (Protiva Biotherapeutics Inc. and Protiva Biotherapeutics (USA), Inc.), foreign currency monetary assets and liabilities are translated into Canadian dollars at the rate of exchange prevailing at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. The previous month’s closing rate of exchange is used to translate revenue and expense transactions. Exchange gains and losses are included in income or loss for the period.

	Effective October 1, 2013, the Company is using United States dollars as its reporting currency. All assets and liabilities are translated using the exchange rate at the balance sheet date (2013 – 0.9402; 2012 – 1.0051; 2011 – 0.9833). Revenues, expenses and other income (losses) are translated using the average rate for the period (2013 – 0.971; 2012 – 1.001; 2011 – 1.012), except for large transactions, for which the exchange rate on the date of the transaction is used. Equity accounts are translated using the historical rate. As a result of the change in reporting currency, the Company is reporting an accumulated other comprehensive loss of $15,825,386 as at December 31, 2013 (2012 - $12,690,640; 2011 – $13,164,466) in its consolidated balance sheets. As the translation differences from the Company’s functional currency of Canadian dollars to the Company’s reporting currency of U.S. dollars are unrealized gains and losses, the differences are recorded in other comprehensive income (loss), and do not impact the calculation of Earnings per Share.
Income Tax, Policy [Policy Text Block]	'
	Deferred income taxes

	Income taxes are accounted for using the asset and liability method of accounting. Deferred income taxes are recognized for the future income tax consequences attributable to differences between the carrying values of assets and liabilities and their respective income tax bases and for loss carry-forwards. Deferred income tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the periods in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax laws or rates is included in earnings in the period that includes the enactment date. When realization of deferred income tax assets does not meet the more-likely-than-not criterion for recognition, a valuation allowance is provided.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-based compensation

	The Company grants stock options to employees and directors pursuant to a share incentive plan described in note 5. Compensation expense is recorded for issued stock options using the fair value method with a corresponding increase in additional paid-in capital. Any consideration received on the exercise of stock options is credited to share capital.

	The fair value of stock options is measured at the grant date and amortized on a straight-line basis over the vesting period
Warrants [Policy Text Block]	'
	Warrants

	The Company accounts for the warrants under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company’s own stock, on the understanding that in compliance with applicable securities laws, the registered warrants require the issuance of registered securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. The Company classifies warrants in its consolidated balance sheet as a liability which is revalued at each balance sheet date subsequent to the initial issuance. The Company uses the Black-Scholes pricing model to value the warrants. Determining the appropriate fair-value model and calculating the fair value of registered warrants requires considerable judgment. A small change in the estimates used may cause a relatively large change in the estimated valuation. The estimated volatility of the Company’s common stock at the date of issuance, and at each subsequent reporting period, is based on historic fluctuations in the Company’s stock price. The risk-free interest rate is based on the zero-coupon rate for bonds with a maturity similar to the expected remaining life of the warrants at the valuation date. The expected life of the warrants is based on the historical pattern of exercises of warrants.
Segment Reporting, Policy [Policy Text Block]	'
	Segment information

	The Company operates in a single reporting segment, the research and development of RNA interference therapeutics. Substantially all of the Company’s revenues to date were earned from customers or collaborators based in the United States. Substantially all of the Company’s premises, property and equipment is located in Canada.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent accounting pronouncements

	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.

	In December 2011, the FASB issued ASU 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities. In January 2013, the FASB issued ASU-2013-01, Balance Sheet: Clarifying the Scope and Disclosures about Offsetting Assets and Liabilities, which narrows the scope of ASU 2011-011. These newly issued accounting standards requires an entity to disclose both gross and net information about instruments and transactions eligible for offset in the balance sheet as well as instruments and transactions executed under a master netting or similar arrangement and was issued to enable users of financial statements to understand the effects or potential effects of those arrangements on its balance sheet. This ASU is required to be applied retrospectively and is effective for fiscal years, and interim periods within those years, beginning on or after January 1, 2013. As this accounting standard only requires enhanced disclosure, the adoption of this standard did not have an impact on the Company’s financial position or statement of operations.

	In February 2013, the FASB issued amendments to the accounting guidance for presentation of comprehensive income to improve the reporting of reclassifications out of accumulated other comprehensive income. The amendments do not change the current requirements for reporting net income or other comprehensive income, but do require an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the statement where the net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under GAAP to be reclassified to net income in its entirety in the same reporting period. For other amounts that are not required under GAAP to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures required under GAAP that provide additional detail about these amounts. For public companies, these amendments are effective prospectively for reporting periods beginning after December 15, 2012. The adoption of this guidance did not impact our consolidated financial statements.

	In July 2013, the FASB issued ASU 2013-11, Income Taxes (ASC 740) Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carry forward, a Similar Tax Loss, or a Tax Credit Carry forward Exists (Update). The update is intended to eliminate the diversity in practice of the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The update is effective for annual and interim financial statements for fiscal years beginning after December 15, 2013. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted.

Note_2_Significant_Accounting_1

Note 2 - Significant Accounting Policies (Tables)	12 Months Ended
Note 2 - Significant Accounting Policies (Tables)	Dec. 31, 2013
Accounting Policies [Abstract]	'
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	'
			Level 1			Level 2		Level 3			31-Dec-13
	Assets
	Cash		$	68,716,531			-		-		$	68,716,531
	Guaranteed Investment Certificates			-			-		-			-
	Total		$	68,716,531			-		-		$	68,716,531

	Liabilities
	Warrants		$	-			-	$	5,378,772		$	5,378,772
			Level 1			Level 2		Level 3			31-Dec-12
	Assets
	Cash		$	44,373,720			-		-		$	44,373,720
	Guaranteed Investment Certificates			2,650,404			-		-			2,650,404
	Total		$	47,024,124			-		-		$	47,024,124

	Liabilities
	Warrants		$	-			-	$	4,014,821		$	4,014,821
Changes In Fair Value Of Warrants [Table Text Block]	'
			Liability at			Opening		Fair value of			Increase			Foreign			Liability
			beginning			liability of		warrants			(decrease) in			exchange			at end
			of the year			warrants issued in		exercised			value of			(gain) loss			of the year
						the year		in the			warrants
								year

	Year ended December 31, 2011		$	-		$	786,919	$	-		$	(579,474	)	$	(5,825	)	$	201,620
	Year ended December 31, 2012		$	201,620		$	850,907	$	(880,691	)	$	3,821,635		$	21,350		$	4,014,821
	Year ended December 31, 2013		$	4,014,821		$	-	$	(1,854,028	)	$	3,530,314		$	(312,335	)	$	5,378,772
Property, Plant and Equipment, Estimated Useful Lives [Table Text Block]	'
		Rate

	Laboratory equipment (years)		5
	Computer and office equipment (years)	2	-	5
	Furniture and fixtures (years)		5
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
			Year ended December 31
			2013			2012		2011
	Numerator:
	Net income (loss)		$	(14,064,226	)	$	29,611,996	$	(10,083,491	)
	Denominator:
	Weighted average number of common shares			15,302,680			13,727,925		11,318,766
	Effect of dilutive securities:
	Warrants			-			177,374		-
	Options			-			415,515		-
	Diluted weighted average number of common shares			15,302,680			14,320,814		11,318,766

	Basic income (loss) per common share		$	(0.92	)	$	2.16	$	(0.89	)

	Diluted income (loss) per common share		$	(0.92	)	$	2.07	$	(0.89	)

Note_3_Collaborations_Contract1

Note 3 - Collaborations, Contracts and Licensing Agreements (Tables)	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]	'
		Year ended December 31
		2013		2012		2011
	Collaborations and contracts
	DoD (a)	$	9,805,556	$	11,536,101	$	11,565,997
	Alnylam (b)		-		9,719		4,191,295
	BMS (c)		525,527		440,279		437,165
	Other RNAi collaborators (d)		93,486		119,087		117,133
	Total research and development collaborations and contracts		10,424,569		12,105,186		16,311,590
	Licensing fees and milestone payments
	Alnylam milestone payments (b)		5,000,000		1,000,000		500,000
	Spectrum payments (e)		39,581		1,000,000		-
	Total licensing fees and milestone payments		5,039,581		2,000,000		500,000
	Total revenue	$	15,464,150	$	14,105,186	$	16,811,590
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	'
		31-Dec-13		31-Dec-12

	DoD (a)	$	1,655,028	$	1,388,970
	BMS current portion (c)		1,808,227		1,754,610
	Deferred revenue, current portion		3,463,255		3,143,580
	BMS long-term portion (c)		-		722,445
	Total deferred revenue	$	3,463,255	$	3,866,025

Note_4_Property_and_Equipment_

Note 4 - Property and Equipment (Tables)	12 Months Ended
Note 4 - Property and Equipment (Tables)	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	31-Dec-13	Cost		Accumulated			Net
	31-Dec-13	Cost		depreciation			book value

	Lab equipment	$	4,885,963	$	(4,678,976	)	$	206,987
	Leashold improvements		5,592,312		(5,001,683	)	$	590,629
	Computer hardware and software		1,991,927		(1,589,519	)	$	402,408
	Furniture and fixtures		395,948		(395,416	)	$	532
	Assets under construction		172,601		-		$	172,601
		$	13,038,751	$	(11,665,594	)	$	1,373,157
	31-Dec-12	Cost		Accumulated			Net
	31-Dec-12	Cost		depreciation			book value

	Lab equipment	$	5,136,975	$	(4,787,905	)	$	349,070
	Leasehold improvements		5,978,338		(5,041,900	)		936,438
	Computer hardware and software		1,649,593		(1,585,288	)		64,305
	Furniture and fixtures		423,281		(421,363	)		1,918
		$	13,188,187	$	(11,836,456	)	$	1,351,731

Note_5_Share_Capital_Tables

Note 5 - Share Capital (Tables)	12 Months Ended
Note 5 - Share Capital (Tables)	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
			Common shares				Weighted average				Weighted				Range of					Range of				Weighted			Aggregate			Aggregate
			purchasable upon				exercise price (C$)				average exercise				exercise prices					exercise prices				average			intrinsic value			intrinsic value
			exercise of								price (US$)				(C$)					(US$)				remaining			(C$)			(US$)
			warrants																					contractual life
																								(years)

	Balance, December 31, 2011			949,495			$	3.25			$	3.2			$1.65	-	$3.35			$1.62	-	$3.29			4.6		$	-		$	-
	Issued			924,302			$	2.6			$	2.61				$2.60					$2.61
	Exercised			(285,386	)		$	2.53			$	2.54			$1.65	-	$3.35			$1.66	-	$3.37
	Balance, December 31, 2012			1,588,411			$	3			$	3.02			$2.50	-	$3.35			$2.51	-	$3.37			3.8			3,140,893			3,156,912
	Issued			-				-				-				-					-
	Exercised			(573,683	)		$	3.19			$	3			$2.60	-	$3.35			$2.44	-	$3.15									-
	Balance, December 31, 2013			1,014,728			$	2.9			$	2.72			$2.60	-	$3.35			$2.44	-	$3.15			2.7		$	5,635,446		$	5,298,447
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
			Year ended December 31
			2013				2012

	Dividend yield			0	%			0	%
	Expected volatility			47.03	%			40	%
	Risk-free interest rate			1.13	%			1.28	%
	Expected average term (years)		1.6				3.8
	Fair value of warrants outstanding		$	5.3			$	2.51
	Aggregate fair value of warrants outstanding		$	5,378,722			$	4,014,821
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
			Number of				Weighted				Weighted				Aggregate				Aggregate
			optioned				average exercise				average exercise				intrinsic				intrinsic
			common shares				price (C$)				price (US$)				value (C$)				value (US$)

	Balance, December 31, 2010			1,083,432			$	7.95			$	7.72			$	756,628			$	734,881
	Options granted			403,100			$	2.14			$	2.17
	Options exercised			(1,667	)		$	1.5			$	1.52			$	1,330			$	1,346
	Options forfeited, cancelled or expired			(71,547	)		$	27.42			$	27.74
	Balance, December 31, 2011			1,413,318			$	5.32			$	5.38			$	1,800			$	1,821
	Options granted			326,300			$	4.16			$	4.16
	Options exercised			(28,417	)		$	2.34			$	2.34			$	81,545			$	81,598
	Options forfeited, cancelled or expired			(62,355	)		$	21.27			$	21.29
	Balance, December 31, 2012			1,648,846			$	4.54			$	4.54			$	2,299,512			$	2,300,996
	Options granted			270,250			$	7.52			$	7.3
	Options exercised			(124,246	)		$	3.22			$	3.13			$	551,385			$	535,369
	Options forfeited, cancelled or expired			(64,085	)		$	21.87			$	21.23
	Balance, December 31, 2013			1,730,765			$	4.45			$	4.32			$	7,029,795			$	6,825,608
Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table Text Block]	'
						Options outstanding December 31, 2013																Options exercisable December 31, 2013
	Range of					Number				Weighted				Weighted				Weighted				Number			Weighted			Weighted
	Exercise prices					of options				average				average				average				of options			average			average
						outstanding				remaining				exercise				exercise				exercisable			exercise			exercise
										contractual				price (C$)				price (US$)							price (C$)			price (US$)
										life (years)

	$1.50	to	$1.90				261,475				6.7			$	1.71			$	1.66				236,475		$	1.71		$	1.66
	$2.10	to	$2.60				279,000				7.7			$	2.32			$	2.25				236,175		$	2.35		$	2.28
	$3.00	to	$3.10				108,979				2.2			$	3.04			$	2.95				108,979		$	3.04		$	2.95
	$3.73	to	$3.85				153,250				6.1			$	3.84			$	3.73				150,650		$	3.85		$	3.74
	$4.38	to	$4.54				21,250				9.2			$	4.53			$	4.4				5,313		$	4.53		$	4.4
	$4.65	to	$5.60				576,846				6.2			$	5.25			$	5.1				474,909		$	5.27		$	5.12
	$5.69	to	$11.60				329,965				7.6			$	7.79			$	7.56				164,590		$	7.45		$	7.23
	$1.50	to	$11.60				1,730,765				6.6			$	4.45			$	4.32				1,377,091		$	4.08		$	3.96
Schedule of Nonvested Share Activity [Table Text Block]	'
			Number of				Weighted				Weighted
			optioned				average				average
			common shares				fair value (C$)				fair value (US$)

	Non-vested at December 31, 2012			333,691			$	3.38			$	3.38

	Options granted			270,250			$	7.52				7.3
	Options vested			(219,966	)		$	4.47				4.34
	Non-vested options forfeited			(30,300	)		$	3.74				3.63
	Non-vested at December 31, 2013			353,675			$	5.44			$	5.28
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]	'
			Year ended December 31
			2013				2012				2011

	Dividend yield			0	%			0	%			0	%
	Expected volatility			111.61	%			120.4	%			116.26	%
	Risk-free interest rate			2.39	%			1.56	%			2.51	%
	Expected average option term (years)			9.6				8.2				9.6
	Fair value of options granted (C$)		$	6.96			$	3.83			$	2
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
			Year ended December 31
			2013				2012				2011

	Research, development, collaborations and contracts expenses		$	621,807			$	772,367			$	500,425
	General and administrative expenses			281,198				209,923				133,024
	Total		$	903,005			$	982,290			$	633,449
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]	'
			Number of Protiva				Equivalent number				Weighted				Weighted
			Options				of Company				average exercise				average
							common shares				price (C$)				exercise price
															(US$)

	Balance, December 31, 2010			518,223				349,883				0.3				0.3
	Options exercised			(27,202	)			(18,366	)			0.3				0.3
	Options forfeited, cancelled or expired			-				-				-				-
	Balance, December 31, 2011			491,020				331,517				0.3				0.3
	Options exercised			(15,135	)			(10,218	)			0.3				0.3
	Options forfeited, cancelled or expired			-				-				-				-
	Balance, December 31, 2012			475,885				321,299			$	0.3			$	0.3
	Options exercised			(2,000	)			(1,350	)			0.3				0.29
	Options forfeited, cancelled or expired			(1,000	)			(675	)			0.3				0.29
	Balance, December 31, 2013			472,885				319,274				0.3				0.29

Note_7_Income_Taxes_Tables

Note 7 - Income Taxes (Tables)	12 Months Ended
Note 7 - Income Taxes (Tables)	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
		Year ended December 31
		2013			2012			2011

	Computed taxes (recoveries) at Canadian federal and provincial tax rates	$	(2,380,267	)	$	7,486,268		$	(2,589,310	)
	Differences due to change in enacted tax rates		(5,723	)		780,963			700,342
	Difference due to change in tax rate on opening deferred taxes		-			2,636,377			3,369,825
	Permanent and other differences		1,820,842			2,202,291			141,587
	Change in valuation allowance		565,147			(2,515,765	)		(1,622,445	)
	Utilization of investment tax credits		-			(10,590,133	)		-
	Income tax (recovery) expense	$	-		$	-		$	-
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
		Year ended December 31
		2013			2012

	Deferred tax assets:
	Non-capital loss carryforwards	$	4,354,066		$	4,561,144
	Research and development deductions		8,858,564			8,583,554
	Book amortization in excess of tax		2,170,922			1,934,818
	Share issue costs		(136,329	)		(26,133	)
	Revenue recognized for tax purposes in excess of revenue recognized for accounting purposes		667,542			-
	Tax value in excess of accounting value in lease inducements		(2,821	)		8,041
	Accounting value in excess of tax value in intangible assets		-			372,892
	Provincial investment tax credits		392,063			304,545
	Total deferred tax assets		16,304,008			15,738,861
	Valuation allowance		(16,304,008	)		(15,738,861	)
	Net deferred tax assets	$	-		$	-

Note_9_Concentrations_of_Busin1

Note 9 - Concentrations of Business Risk (Tables)	12 Months Ended
Note 9 - Concentrations of Business Risk (Tables)	Dec. 31, 2013
Risks and Uncertainties [Abstract]	'
Net Liquidity Disclosure [Table Text Block]	'
		31-Dec-13			31-Dec-12
	Cash, cash equivalents and short term investments	$	68,716,531		$	47,024,124
	Less: Accounts payable and accrued liabilities		(3,680,462	)		(3,795,546	)
		$	65,036,069		$	43,228,578
Schedule of Intercompany Foreign Currency Balances [Table Text Block]	'
	(in C$)	31-Dec-13			31-Dec-12
	Cash and cash equivalents	$	38,900,944		$	149,058
	Accounts receivable		10,840			1,025,306
	Accrued revenue		225,892			2,361,836
	Accounts payable and accrued liabilities		(1,889,480	)		(2,969,454	)
		$	37,248,196		$	566,746

Note_10_Supplementary_Informat1

Note 10 - Supplementary Information (Tables)	12 Months Ended
Note 10 - Supplementary Information (Tables)	Dec. 31, 2013
Disclosure Text Block Supplement [Abstract]	'
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	'
		31-Dec-13		31-Dec-12

	Trade accounts payable	$	1,217,242	$	805,790
	Research and development accruals		1,404,905		310,492
	License fee accruals		-		1,649,957
	Professional fee accruals		247,148		602,113
	Deferred lease inducements		16,454		48,078
	Other accrued liabilities		794,713		379,116
		$	3,680,462	$	3,795,546

Note_12_Interim_Financial_Data1

Note 12 - Interim Financial Data (unaudited) (Tables)	12 Months Ended
Note 12 - Interim Financial Data (unaudited) (Tables)	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of Quarterly Financial Information [Table Text Block]	'
			2013
			Q1			Q2			Q3			Q4		Total

	Revenue		2,131,519			2,843,806			2,962,809			7,526,016			15,464,150

	Loss from operations		(2,993,811	)		(3,070,968	)		(3,652,191	)		(2,436,248	)		(12,153,218	)

	Net loss		(2,546,244	)		(3,014,928	)		(5,905,923	)		(2,597,131	)		(14,064,226	)

	Basic and diluted net loss per share	$	(0.18	)	$	(0.21	)	$	(0.41	)	$	(0.15	)	$	(0.92	)
			2012
			Q1			Q2			Q3			Q4		Total

	Revenue		3,586,970			3,643,296			3,067,593			3,807,327			14,105,186

	Loss from operations		(2,651,931	)		(2,599,027	)		(1,784,666	)		(5,908,924	)		(12,944,548	)

	Net (loss) income		(3,180,259	)		(1,935,761	)		(3,457,600	)		38,185,616			29,611,996

	Basic net (loss) income per share	$	(0.25	)	$	(0.14	)	$	(0.25	)	$	2.72		$	2.16

	Diluted net (loss) income per share	$	(0.25	)	$	(0.14	)	$	(0.25	)	$	2.51		$	2.07

Note_2_Significant_Accounting_2

Note 2 - Significant Accounting Policies (Details) (USD $)	12 Months Ended
Note 2 - Significant Accounting Policies (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Note 2 - Significant Accounting Policies (Details) [Line Items]	'	'	'
Wholly Owned Subsidiaries	2	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)	3,064,767	1,085,503	2,694,330
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax (in Dollars)	$15,825,386	$12,690,640	$13,164,466
Assets And Liabilities [Member]	'	'	'
Note 2 - Significant Accounting Policies (Details) [Line Items]	'	'	'
Foreign Currency Exchange Rate, Translation	0.9402	1.0051	0.9833
Revenues And Expenses [Member]	'	'	'
Note 2 - Significant Accounting Policies (Details) [Line Items]	'	'	'
Foreign Currency Exchange Rate, Translation	0.971	1.001	1.012

Note_2_Significant_Accounting_3

Note 2 - Significant Accounting Policies (Details) - Assets and Liabilities Measured at Fair Value (USD $)	Dec. 31, 2013	Dec. 31, 2012
Note 2 - Significant Accounting Policies (Details) - Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Cash	$68,716,531	$44,373,720
Guaranteed Investment Certificates	'	2,650,404
Total	68,716,531	47,024,124
Warrants	5,378,772	4,014,821
Fair Value, Inputs, Level 1 [Member]	'	'
Note 2 - Significant Accounting Policies (Details) - Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Cash	68,716,531	44,373,720
Guaranteed Investment Certificates	'	2,650,404
Total	68,716,531	47,024,124
Fair Value, Inputs, Level 3 [Member]	'	'
Note 2 - Significant Accounting Policies (Details) - Assets and Liabilities Measured at Fair Value [Line Items]	'	'
Warrants	$5,378,772	$4,014,821

Note_2_Significant_Accounting_4

Note 2 - Significant Accounting Policies (Details) - Changes in Fair Value of the Companybs Warrants (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Note 2 - Significant Accounting Policies (Details) - Changes in Fair Value of the Companybs Warrants [Line Items]	'	'	'
Liability at beginning of the period	$4,014,821	'	'
Opening liability of warrants issued in the period	'	850,907	751,505
Foreign exchange (gain) loss	-3,530,314	-3,821,635	579,474
Liability at end of the period	5,378,772	4,014,821	'
Change In Fair Value [Member]	'	'	'
Note 2 - Significant Accounting Policies (Details) - Changes in Fair Value of the Companybs Warrants [Line Items]	'	'	'
Liability at beginning of the period	4,014,821	201,620	'
Opening liability of warrants issued in the period	'	850,907	786,919
Fair value of warrants exercised in the period	-1,854,028	-880,691	'
Increase (decrease) in value of warrants	3,530,314	3,821,635	-579,474
Foreign exchange (gain) loss	-312,335	21,350	-5,825
Liability at end of the period	$5,378,772	$4,014,821	$201,620

Note_2_Significant_Accounting_5

Note 2 - Significant Accounting Policies (Details) - Estimated Useful Lives	12 Months Ended
	Dec. 31, 2013
Laboratory Equipment [Member]	'
Note 2 - Significant Accounting Policies (Details) - Estimated Useful Lives [Line Items]	'
Useful Lives	'5 years
Computer Equipment [Member] \| Minimum [Member]	'
Note 2 - Significant Accounting Policies (Details) - Estimated Useful Lives [Line Items]	'
Useful Lives	'2 years
Computer Equipment [Member] \| Maximum [Member]	'
Note 2 - Significant Accounting Policies (Details) - Estimated Useful Lives [Line Items]	'
Useful Lives	'5 years
Furniture and Fixtures [Member]	'
Note 2 - Significant Accounting Policies (Details) - Estimated Useful Lives [Line Items]	'
Useful Lives	'5 years

Note_2_Significant_Accounting_6

Note 2 - Significant Accounting Policies (Details) - Computation of Basic and Diluted Net Income (Loss) per Common Share (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Note 2 - Significant Accounting Policies (Details) - Computation of Basic and Diluted Net Income (Loss) per Common Share [Line Items]	'	'	'
Net income (loss)	($14,064,226)	$29,611,996	($10,083,491)
Weighted average number of common shares	15,302,680	13,727,925	11,318,766
Diluted weighted average number of common shares	15,302,680	14,320,814	11,318,766
Basic income (loss) per common share	($0.92)	$2.16	($0.89)
Diluted income (loss) per common share	($0.92)	$2.07	($0.89)
Warrant [Member]	'	'	'
Note 2 - Significant Accounting Policies (Details) - Computation of Basic and Diluted Net Income (Loss) per Common Share [Line Items]	'	'	'
Dilutive Securities	'	177,374	'
Options Held [Member]	'	'	'
Note 2 - Significant Accounting Policies (Details) - Computation of Basic and Diluted Net Income (Loss) per Common Share [Line Items]	'	'	'
Dilutive Securities	'	$415,515	'

Note_3_Collaborations_Contract2

Note 3 - Collaborations, Contracts and Licensing Agreements (Details) (USD $)

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Jun. 21, 2013

Dec. 10, 2012

Nov. 12, 2012

Nov. 26, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

8-May-13

Jul. 14, 2010

10-May-10

Jan. 01, 2009

Nov. 26, 2012

Dec. 31, 2012

Dec. 31, 2013

Jul. 14, 2010

Dec. 31, 2013

Nov. 30, 2013

Jun. 30, 2012

Dec. 31, 2012

Dec. 31, 2013

Provision Of Staff [Member]

Termination Of Manufacturing Agreement [Member]

Termination Of Prior License Agreements [Member]

Talon Therapeutics [Member]

Merck [Member]

Contract Extension [Member]

Cross License Agreement [Member]

Alnylam License Agreement [Member]

Marqibo Commercial Sales [Member]

Marqibo [Member]

Maximum [Member]

Acquired Intellectual Property [Member]

Acquired Intellectual Propert First One [Member]

Note 3 - Collaborations, Contracts and Licensing Agreements (Details) [Line Items]

Potential Contract Funding Amount

$41,700,000

$34,700,000

$11,200,000

$18,000,000

$17,000,000

$15,000,000

$140,000,000

License Costs

300,000

8,500,000

100,000

1,500,000

License amendment payment

65,000,000

30,000,000

35,000,000

Legal Fees

18,737,966

Licenses Revenue

5,000,000

5,039,581

2,000,000

500,000

5,000,000

375,000

1,000,000

Deferred Revenue

3,000,000

Contracts Revenue

10,424,569

12,105,186

16,311,590

1,000,000

Royalty Revenue

39,581

Accrued Contract Revenue

$990

Note_3_Collaborations_Contract3

Note 3 - Collaborations, Contracts and Licensing Agreements (Details) - Revenue Recognized Under Collaborations, Contracts and Licensing Agreements (USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Collaborations and contracts	'		'		'
Collaborations, Contracts, Licensing Fees, Milestone payments	$10,424,569		$12,105,186		$16,311,590
Total revenue	15,464,150		14,105,186		16,811,590
Alnylam [Member]	'		'		'
Collaborations and contracts	'		'		'
Collaborations, Contracts, Licensing Fees, Milestone payments	5,000,000	[1]	1,000,000	[1]	500,000	[1]
Spectrum [Member]	'		'		'
Collaborations and contracts	'		'		'
Collaborations, Contracts, Licensing Fees, Milestone payments	39,581	[2]	1,000,000	[2]	'	[2]
Total [Member]	'		'		'
Collaborations and contracts	'		'		'
Collaborations, Contracts, Licensing Fees, Milestone payments	5,039,581		2,000,000		500,000
DoD [Member]	'		'		'
Collaborations and contracts	'		'		'
Collaborations, Contracts, Licensing Fees, Milestone payments	9,805,556	[3]	11,536,101	[3]	11,565,997	[3]
Alnylam [Member]	'		'		'
Collaborations and contracts	'		'		'
Collaborations, Contracts, Licensing Fees, Milestone payments	'	[1]	9,719	[1]	4,191,295	[1]
BMS [Member]	'		'		'
Collaborations and contracts	'		'		'
Collaborations, Contracts, Licensing Fees, Milestone payments	525,527	[4]	440,279	[4]	437,165	[4]
Other RNAi Collaborators [Member]	'		'		'
Collaborations and contracts	'		'		'
Collaborations, Contracts, Licensing Fees, Milestone payments	93,486	[1]	119,087	[1]	117,133	[1]
Total [Member]	'		'		'
Collaborations and contracts	'		'		'
Collaborations, Contracts, Licensing Fees, Milestone payments	$10,424,569		$12,105,186		$16,311,590

[1]	License and collaboration with Alnylam Pharmaceuticals, Inc. ("Alnylam") License and Collaboration Agreement with Alnylam through TekmiraOn January 8, 2007, the Company entered into a licensing and collaboration agreement with Alnylam ("Alnylam License and Collaboration"), which was amended and restated in May 2008, giving them an exclusive license to certain of the Company's historical lipid nanoparticle intellectual property for the discovery, development, and commercialization of ribonucleic acid interference ("RNAi") therapeutics. The Alnylam License and Collaboration was replaced by a new license agreement as part of the settlement, which is discussed below. Cross-License with Alnylam acquired through Protiva As a result of the acquisition of Protiva on May 30, 2008, the Company acquired a Cross-License Agreement between Protiva and Alnylam (the "Alnylam Cross-License"). Alnylam was granted a non-exclusive license to the Protiva intellectual property. The Alnylam Cross-License was replaced by a new license agreement as part of the settlement, which is discussed below. Manufacturing agreement with Alnylam Under a manufacturing agreement with Alnylam (the "Alnylam Manufacturing Agreement") effective January 1, 2009, the Company was the exclusive manufacturer of any products required by Alnylam through to the end of Phase 2 clinical trials that utilize the Company's technology. Alnylam was paying the Company for the provision of staff and for external costs incurred. Time charged to Alnylam was at a fixed rate and under the Alnylam Manufacturing Agreement there was a contractual minimum for the provision of staff of $11,200,000 over the three year period ending December 31, 2011. The Alnylam Manufacturing Agreement was terminated as part of the settlement which is discussed below. Settlement of litigation with Alnylam and Acuitas Therapeutics Inc. ("Acuitas", formerly AlCana Technologies Inc.) On March 16, 2011 the Company filed a complaint against Alnylam. On November 12, 2012, the Company entered into an agreement to settle all litigation between the Company and Alnylam and Acuitas (the "Settlement") and also entered into a new licensing agreement with Alnylam that replaces all earlier licensing, cross-licensing, collaboration, and manufacturing agreements. The Company entered into a separate cross license agreement with Acuitas which includes milestone and royalty payments and Acuitas has agreed not to compete in the RNAi field for five years. In conjunction with the Settlement, the Company paid Acuitas $300,000. The Company paid a further $1,500,000 upon the execution of the cross license agreement with Acuitas, in the year ended December 31, 2013. As a result of the new Alnylam license agreement, on November 26, 2012, the Company received $65,000,000 in cash from Alnylam. This includes $30,000,000 associated with the termination of the manufacturing agreement and $35,000,000 associated with the termination of the previous license agreements, as well as a modification of the milestone and royalty schedules associated with Alnylam's ALN-VSP, ALN-PCS, and ALN-TTR programs. Under the settlement, Alnylam received license rights to the Company's patents that were filed, or that claim priority to a patent that was filed, before April 15, 2010. Alnylam does not have rights to the Company's patents filed after April 15, 2010 unless they claim priority to a patent filed before that date. In addition, Alnylam has transferred all agreed upon patents and patent applications related to lipid nanoparticle ("LNP") technology for the systemic delivery of RNAi therapeutic products, including the MC3 lipid family, to the Company, who will own and control prosecution of this intellectual property portfolio. The Company is the only entity able to sublicense its LNP intellectual property in future platform-type relationships. Alnylam has a license to use the Company's intellectual property to develop and commercialize products and may only grant access to the Company's LNP technology to its partners if it is part of a product sublicense. Alnylam will pay the Company milestones and royalties as Alnylam's LNP-enabled products are developed and commercialized.The new licensing agreement with Alnylam also grants the Company intellectual property rights to develop its own proprietary RNAi therapeutics. Alnylam has granted the Company a worldwide license for the discovery, development and commercialization of RNAi products directed to thirteen gene targets - three exclusive and ten non-exclusive licenses - provided that they have not been committed by Alnylam to a third party or are not otherwise unavailable as a result of the exercise of a right of first refusal held by a third party or are part of an ongoing or planned development program of Alnylam. Licenses for five of the ten non-exclusive targets - ApoB, PLK1, Ebola, WEE1, and CSN5 - have already been granted, along with an additional license for ALDH2, which has been granted on an exclusive basis. In consideration for this license, the Company has agreed to pay single-digit royalties to Alnylam on product sales and have milestone obligations of up to $8,500,000 on the non-exclusive licenses (with the exception of TKM-Ebola, which has no milestone obligations). Alnylam no longer has "opt-in" rights to the Company's lead oncology product, TKM-PLK1, so the Company now holds all development and commercialization rights related TKM-PLK1. The Company will have no milestone obligations on the three exclusive licenses. As a result of the settlement of the litigation between the Company and Alnylam, $18,737,966 in a contingent obligation payment to Orrick, Herrington and Sutcliffe LLP ("Orrick"), lead legal counsel for the lawsuit against Alnylam and Acuitas, was paid out on December 10, 2012. Milestone receipts and payments In June 2012 the Company earned a $1,000,000 milestone from Alnylam in respect of the initiation of Alnylam's ALN-TTR02 Phase 2 human clinical trial. In November 2013, Alnylam initiated a Phase III trial with ALN-TTR02, also known as patisiran, and the associated $5,000,000 development milestone was paid to the Company in December 2013. In November 2013, the Company initiated Phase I/II clinical trial for TKM-PLK1, resulting in a milestone payment of $375,000 to Alnylam. Arbitration with Alnylam and Ascletis Pharmaceuticals (Hangzhou) Co. Ltd. ("Ascletis") On June 21, 2013, the Company transferred manufacturing process technology to Ascletis to enable them to produce ALN-VSP, a product candidate licensed to them by Alnylam. The Company believes that under the new licensing agreement with Alnylam, the technology transfer to Ascletis triggers a $5,000,000 milestone obligation from Alnylam to the Company. However, Alnylam has demanded a declaration that the Company has not yet met its milestone obligations. The Company disputes Alnylam's position. To remedy this dispute, the Company and Alnylam have commenced arbitration proceedings as provided for under the agreement. The Company has not recorded any revenue in respect of this milestone.
[2]	Agreements with Spectrum Pharmaceuticals, Inc. ("Spectrum") On May 6, 2006, the Company signed a number of agreements with Talon Therapeutics, Inc. ("Talon", formerly Hana Biosciences, Inc.) including the grant of worldwide licenses (the "Talon License Agreement") for three of the Company's chemotherapy products, Marqibo, AlocrestTM (Optisomal Vinorelbine) and BrakivaTM (Optisomal Topotecan). On August 9, 2012, the Company announced that Talon had received accelerated approval for Marqibo from the FDA for the treatment of adult patients with Philadelphia chromosome negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Marqibo is a liposomal formulation of the chemotherapy drug vincristine. In the year ended December 31, 2012, the Company received a milestone of $1,000,000 based on the FDA's approval of Marqibo and will receive royalty payments based on Marqibo's commercial sales. There are no further milestones related to Marqibo but the Company is eligible to receive total milestone payments of up to $18,000,000 on Alocrest and Brakiva. Talon was acquired by Spectrum in July 2013. The acquisition does not affect the terms of the license between Talon and the Company. On September 3, 2013, Spectrum announced that they had shipped the first commercial orders of Marqibo. In the year ended December 31, 2013, the Company recorded $39,581 in Marqibo royalty revenue (2012 - $nil, 2011 - $nil). In the year ended December 31, 2013, the Company accrued $990 in royalties due to TPC in respect of the Marqibo royalty earned by the Company (see note 8).
[3]	Contract with United States Government's Department of Defense ("DoD") to develop TKM-Ebola On July 14, 2010, the Company signed a contract with the DoD to advance TKM-Ebola, an RNAi therapeutic utilizing the Company's lipid nanoparticle technology to treat Ebola virus infection. In the initial phase of the contract, funded as part of the Transformational Medical Technologies program, the Company is eligible to receive up to $34.7 million. This initial funding is for the development of TKM-Ebola including completion of preclinical development, filing an Investigational New Drug application with the United States Food and Drug Administration ("FDA") and completing a Phase 1 human safety clinical trial. On May 8, 2013, the Company announced that the contract had been modified to support development plans that integrate recent advancements in lipid nanoparticle ("LNP") formulation and manufacturing technologies. The contract modification increased the stage one targeted funding to $41.7 million.The DoD has the option of extending the contract beyond the initial funding period to support the advancement of TKM-Ebola through to the completion of clinical development and FDA approval. Based on the contract's budget this would provide the Company with up to $140.0 million in funding for the entire program.Under the contract, the Company is reimbursed for costs incurred, including an allocation of overhead costs, and is paid an incentive fee. At the beginning of the fiscal year the Company estimates its labour and overhead rates for the year ahead. At the end of the year the actual labour and overhead rates are calculated and revenue is adjusted accordingly. The Company's actual labour and overhead rates will differ from its estimated rates based on actual costs incurred and the proportion of the Company's efforts on contracts and internal products versus indirect activities. Within minimum and maximum collars, the amount of incentive fee the Company can earn under the contract varies based on costs incurred versus budgeted costs. During the contractual period, incentive fee revenue and total costs are impacted by management's estimate and judgments which are continuously reviewed and adjusted as necessary using the cumulative catch-up method. At December 31, 2012, the Company was not able to make a reliable estimate of the final contract costs, and only the minimum incentive fee achievable and earned was recognized. At December 31, 2013, the Company believes it can reliably estimate the final contract costs so has recognized the portion of expected incentive fee which has been earned to date. On August 6, 2012, the Company announced that it had received a temporary stop-work order from the DoD in respect of this contract. On October 2, 2012, the Company announced that the stop-work order had been lifted and work on the contract resumed. On November 1, 2012, the Company submitted a contract modification request to the DoD in order to integrate recent advancements in the Company's formulation technology. The modification request is currently being negotiated while work is continuing on the contract.
[4]	Bristol-Myers Squibb ("BMS") collaboration On May 10, 2010 the Company announced the expansion of its research collaboration with BMS. Under the new agreement, BMS uses small interfering RNA ("siRNA") molecules formulated by the Company in LNP technology to silence target genes of interest. BMS is conducting the preclinical work to validate the function of certain genes and share the data with the Company. The Company can use the preclinical data to develop RNAi therapeutic drugs against the therapeutic targets of interest. The Company received $3,000,000 from BMS concurrent with the signing of the agreement and recorded the amount as deferred revenue. The Company is required to provide a pre-determined number of LNP batches over the four-year agreement. BMS has a first right to negotiate a licensing agreement on certain RNAi products developed by the Company that evolve from BMS validated gene targets. Revenue from the May 10, 2010 agreement with BMS is being recognized as the Company produces the related LNP batches. As at December 31, 2013, the Company and BMS intend to extend the agreement's end date from May 10, 2014 to December 31, 2014. Extending the agreement will give BMS more time to order LNP batches. There will not be any monetary consideration for extending the agreement. Revenue recognized in 2013 has been reduced and the balance of deferred revenue as at December 31, 2013 has been increased to account for BMS, potentially, ordering more batches under the agreement.

Note_3_Collaborations_Contract4

Note 3 - Collaborations, Contracts and Licensing Agreements (Details) - Deferred Collaborations and Contracts Revenue

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

CAD

DoD [Member]

BMS [Member]

Total [Member]

USD ($)

Deferred Revenue Arrangement [Line Items]

Deferred Revenue Current Portion

3,463,255

3,143,580

$1,655,028

[1]

$1,388,970

[1]

$1,808,227

[2]

$1,754,610

[2]

$3,463,255

$3,143,580

Deferred Revenue Long-term Portion

722,445

[2]

$722,445

[2]

$3,463,255

$3,866,025

[1]

Contract with United States Government's Department of Defense ("DoD") to develop TKM-Ebola On July 14, 2010, the Company signed a contract with the DoD to advance TKM-Ebola, an RNAi therapeutic utilizing the Company's lipid nanoparticle technology to treat Ebola virus infection. In the initial phase of the contract, funded as part of the Transformational Medical Technologies program, the Company is eligible to receive up to $34.7 million. This initial funding is for the development of TKM-Ebola including completion of preclinical development, filing an Investigational New Drug application with the United States Food and Drug Administration ("FDA") and completing a Phase 1 human safety clinical trial. On May 8, 2013, the Company announced that the contract had been modified to support development plans that integrate recent advancements in lipid nanoparticle ("LNP") formulation and manufacturing technologies. The contract modification increased the stage one targeted funding to $41.7 million.The DoD has the option of extending the contract beyond the initial funding period to support the advancement of TKM-Ebola through to the completion of clinical development and FDA approval. Based on the contract's budget this would provide the Company with up to $140.0 million in funding for the entire program.Under the contract, the Company is reimbursed for costs incurred, including an allocation of overhead costs, and is paid an incentive fee. At the beginning of the fiscal year the Company estimates its labour and overhead rates for the year ahead. At the end of the year the actual labour and overhead rates are calculated and revenue is adjusted accordingly. The Company's actual labour and overhead rates will differ from its estimated rates based on actual costs incurred and the proportion of the Company's efforts on contracts and internal products versus indirect activities. Within minimum and maximum collars, the amount of incentive fee the Company can earn under the contract varies based on costs incurred versus budgeted costs. During the contractual period, incentive fee revenue and total costs are impacted by management's estimate and judgments which are continuously reviewed and adjusted as necessary using the cumulative catch-up method. At December 31, 2012, the Company was not able to make a reliable estimate of the final contract costs, and only the minimum incentive fee achievable and earned was recognized. At December 31, 2013, the Company believes it can reliably estimate the final contract costs so has recognized the portion of expected incentive fee which has been earned to date. On August 6, 2012, the Company announced that it had received a temporary stop-work order from the DoD in respect of this contract. On October 2, 2012, the Company announced that the stop-work order had been lifted and work on the contract resumed. On November 1, 2012, the Company submitted a contract modification request to the DoD in order to integrate recent advancements in the Company's formulation technology. The modification request is currently being negotiated while work is continuing on the contract.

[2]

Bristol-Myers Squibb ("BMS") collaboration On May 10, 2010 the Company announced the expansion of its research collaboration with BMS. Under the new agreement, BMS uses small interfering RNA ("siRNA") molecules formulated by the Company in LNP technology to silence target genes of interest. BMS is conducting the preclinical work to validate the function of certain genes and share the data with the Company. The Company can use the preclinical data to develop RNAi therapeutic drugs against the therapeutic targets of interest. The Company received $3,000,000 from BMS concurrent with the signing of the agreement and recorded the amount as deferred revenue. The Company is required to provide a pre-determined number of LNP batches over the four-year agreement. BMS has a first right to negotiate a licensing agreement on certain RNAi products developed by the Company that evolve from BMS validated gene targets. Revenue from the May 10, 2010 agreement with BMS is being recognized as the Company produces the related LNP batches. As at December 31, 2013, the Company and BMS intend to extend the agreement's end date from May 10, 2014 to December 31, 2014. Extending the agreement will give BMS more time to order LNP batches. There will not be any monetary consideration for extending the agreement. Revenue recognized in 2013 has been reduced and the balance of deferred revenue as at December 31, 2013 has been increased to account for BMS, potentially, ordering more batches under the agreement.

Note_4_Property_and_Equipment_1

Note 4 - Property and Equipment (Details) (USD $)	12 Months Ended
Note 4 - Property and Equipment (Details) (USD $)	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Asset Impairment Charges	$0

Note_4_Property_and_Equipment_2

Note 4 - Property and Equipment (Details) - Property and Equipment Summary (CAD)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Cost	13,038,751	13,188,186
Accumulated depreciation and impairment	-11,665,594	-11,836,456
Net book value	1,373,157	1,351,730
Laboratory Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	4,885,963	5,136,975
Accumulated depreciation and impairment	-4,678,976	-4,787,905
Net book value	206,987	349,070
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	5,592,312	5,978,338
Accumulated depreciation and impairment	-5,001,683	-5,041,900
Net book value	590,629	936,438
Computer And Office Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	1,991,927	1,649,593
Accumulated depreciation and impairment	-1,589,519	-1,585,288
Net book value	402,408	64,305
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	395,948	423,281
Accumulated depreciation and impairment	-395,416	-421,363
Net book value	532	1,918
Asset under Construction [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	172,601	'
Net book value	172,601	'

Note_5_Share_Capital_Details

Note 5 - Share Capital (Details)

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

Nov. 02, 2013

Oct. 22, 2013

Feb. 29, 2012

Jun. 16, 2011

Nov. 02, 2013

Jun. 22, 2011

30-May-08

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Jun. 20, 2012

Feb. 29, 2012

Jun. 16, 2011

Dec. 31, 2013

30-May-08

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2012

Jun. 22, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Feb. 29, 2012

Jun. 16, 2011

Feb. 29, 2012

Jun. 16, 2011

Dec. 31, 2013

Jun. 22, 2011

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

Cashless Exercise Provision [Member]

Options Expected To Vest [Member]

Non-Vested Stock Option Activity [Member]

Revised New Common Shares [Member]

Protiva Share Options [Member]

Cashless Exercise Provision [Member]

2007 Plan [Member]

2011 Plan [Member]

2007 Plan And 2011 Plan [Member]

All Share Based Compensation Plans [Member]

Issuance Costs Allocated To Shares [Member]

Issuance Costs Allocated To Warrants [Member]

Revised Amount [Member]

Original Amount [Member]

Maximum [Member]

USD ($)

CAD

USD ($)

Note 5 - Share Capital (Details) [Line Items]

Stock Issued During Period, Shares, New Issues (in Shares)

562,500

3,750,000

1,848,601

1,789,900

Sale of Stock, Price Per Share

$2.20

$2.88

2.2

2.85

Stock Issued During Period, Value, New Issues

$4,069,547

$5,160,934

$32,038,317

$3,040,119

$3,928,294

Share Price (in Dollars per share)

2.6

3.35

Proceeds from Issuance of Common Stock

34,500,000

30,000,000

4,598,862

32,038,317

3,843,996

4,598,862

Unit Issuance Cost

225,551

562,072

178,521

481,135

47,030

80,937

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

894,950

1,014,728

1,588,411

949,495

Warrants and Rights Outstanding

850,907

751,505

5,378,722

5,378,772

4,014,821

Fair Value Assumptions, Risk Free Interest Rate

1.44%

2.19%

1.13%

1.28%

0.00%

Fair Value Assumptions, Expected Volatility Rate

40.00%

47.03%

40.00%

47.03%

40.00%

Fair Value Assumptions, Expected Dividend Rate

0.00%

Fair Value Assumptions, Expected Term

'5 years

'1 year 219 days

'3 years 292 days

'1 year 219 days

Proceeds from Issuance of Private Placement

3,843,995

Class of Warrant or Right, Outstanding (in Shares)

924,302

Payments of Stock Issuance Costs

2,461,683

Proceeds From Issuance Of Common Stock Net

32,038,317

Warrants Exercised (in Shares)

105,683

230,841

468,000

54,545

Proceeds from Warrant Exercises

288,824

632,282

Stock Issued During Period, Shares, Conversion of Convertible Securities (in Shares)

199,765

38,644

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)

273,889

550,726

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

'10 years

'9 years 219 days

'8 years 73 days

'9 years 219 days

'10 years

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'3 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in Shares)

1,377,091

1,315,155

1,015,224

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

$5.30

4.08

$2.51

$3.96

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term

'9 years 73 days

'2 years 36 days

'5 years 328 days

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value

5,869,668

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price

$4.32

4.45

$5.73

5.9

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value

942,918

450,620

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value

954,534

1,071,240

355,657

Percentage Of Options Expected To Vest

98.00%

Annual Forfeiture Rate

2.00%

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized

1,619,451

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'15 months

Common Stock, Capital Shares Reserved for Future Issuance (in Shares)

350,457

519,073

Investment Options, Exercise Price (in Dollars per share)

0.3

Conversion of Stock, Shares Converted (in Shares)

0.6752

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value

6,825,608

7,029,795

3,866,368

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value

$18,941

$8,265

$43,114

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares)

1,730,765

2,050,039

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)

216,523

Note_5_Share_Capital_Details_S

Note 5 - Share Capital (Details) - Summary of Warrant Activity

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 16, 2011

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

USD ($)

CAD

USD ($)

CAD

Issued [Member]

Exercised [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Class of Warrant or Right [Line Items]

Common shares purchasable upon exercise of warrants (in Shares)

1,014,728

1,588,411

949,495

894,950

924,302

-573,683

-285,386

Weighted average exercise price (in Dollars and Dollars)

2.72

2.9

3.02

3.2

3.25

2.61

2.6

3.19

2.54

2.53

Range of exercise prices (in Dollars and Dollars)

2.61

2.6

2.44

2.6

1.66

1.65

3.15

3.35

3.37

3.35

2.44

2.6

2.51

2.5

1.62

1.65

3.15

3.35

3.37

3.35

3.29

3.35

Weighted average remaining contractual life

'2 years 255 days

'3 years 292 days

'4 years 219 days

Aggregate intrinsic value (in Dollars and Dollars)

$5,298,447

5,635,446

$3,156,912

3,140,893

Note_5_Share_Capital_Details_B

Note 5 - Share Capital (Details) - Black-Scholes Option-Pricing Assumptions	1 Months Ended	0 Months Ended	12 Months Ended
	Feb. 29, 2012	Jun. 16, 2011	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012
	USD ($)	USD ($)	USD ($)	CAD	USD ($)	CAD
Black-Scholes Option-Pricing Assumptions [Abstract]	'	'	'	'	'	'
Dividend yield	0.00%	0.00%	0.00%	0.00%	0.00%	'
Expected volatility	40.00%	40.00%	47.03%	47.03%	40.00%	'
Risk-free interest rate	1.44%	2.19%	1.13%	1.13%	1.28%	'
Expected average term (years)	'5 years	'5 years	'1 year 219 days	'1 year 219 days	'3 years 292 days	'
Fair value of warrants outstanding (in Dollars per share)	'	'	$5.30	4.08	$2.51	'
Aggregate fair value of warrants outstanding (in Dollars)	$850,907	$751,505	$5,378,722	5,378,772	$4,014,821	4,014,821

Note_5_Share_Capital_Details_S1

Note 5 - Share Capital (Details) - Stock Option Activity

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

USD ($)

CAD

Total [Member]

Granted [Member]

Exercised [Member]

Forfeited, Cancelled or Expired [Member]

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

Note 5 - Share Capital (Details) - Stock Option Activity [Line Items]

Number of optioned common shares

1,730,765

1,648,846

1,413,318

1,083,432

270,250

326,300

403,100

-124,246

-28,417

-1,667

-64,085

-62,355

-71,547

Weighted average exercise price

$4.32

4.45

$4.54

4.54

$5.38

5.32

$7.72

7.95

$7.30

7.52

$4.16

4.16

$2.17

2.14

$3.13

3.22

$2.34

2.34

$1.52

1.5

$21.23

21.87

$21.29

21.27

$27.74

27.42

Aggregate intrinsic value

$6,825,608

7,029,795

$2,300,996

2,299,512

$1,821

1,800

$734,881

756,628

$535,369

551,385

$81,598

81,545

$1,346

1,330

Note_5_Share_Capital_Details_S2

Note 5 - Share Capital (Details) - Stock Options Outstanding

Dec. 31, 2013

USD ($)

CAD

Outstanding [Member]

Exercisable [Member]

Exercise Price 1.50 To 1.90 [Member]

Exercise Price 2.10 To 2.60 [Member]

Exercise Price 3.00 To 3.10 [Member]

Exercise Price 3.73 To 3.85 [Member]

Exercise Price 4.38 To 4.54 [Member]

Exercise Price 4.65 To 5.60 [Member]

Exercise Price 5.69 To 11.60 [Member]

Exercise Price 1.50 To 11.60 [Member]

Exercise Price 1.50 To 1.90 [Member]

Exercise Price 2.10 To 2.60 [Member]

Exercise Price 3.00 To 3.10 [Member]

Exercise Price 3.73 To 3.85 [Member]

Exercise Price 4.38 To 4.54 [Member]

Exercise Price 4.65 To 5.60 [Member]

Exercise Price 5.69 To 11.60 [Member]

Exercise Price 1.50 To 11.60 [Member]

Exercise Price 1.50 To 1.90 [Member]

Exercise Price 2.10 To 2.60 [Member]

Exercise Price 3.00 To 3.10 [Member]

Exercise Price 3.73 To 3.85 [Member]

Exercise Price 4.38 To 4.54 [Member]

Exercise Price 4.65 To 5.60 [Member]

Exercise Price 5.69 To 11.60 [Member]

Exercise Price 1.50 To 11.60 [Member]

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

Note 5 - Share Capital (Details) - Stock Options Outstanding [Line Items]

Range of Exercise prices - Low

$1.50

$2.10

$3.73

$4.38

$4.65

$5.69

$1.50

Range of Exercise prices - High

$1.90

$2.60

$3.10

$3.85

$4.54

$5.60

$11.60

Number of options outstanding (in Shares)

261,475

279,000

108,979

153,250

21,250

576,846

329,965

1,730,765

Weighted average remaining contractual life (years)

'6 years 255 days

'7 years 255 days

'2 years 73 days

'6 years 36 days

'9 years 73 days

'6 years 73 days

'7 years 219 days

'6 years 219 days

Weighted average exercise price

$4.32

4.45

$1.66

1.71

$2.25

2.32

$2.95

3.04

$3.73

3.84

$4.40

4.53

$5.10

5.25

$7.56

7.79

$4.32

4.45

Number of options exercisable (in Shares)

236,475

236,175

108,979

150,650

5,313

474,909

164,590

1,377,091

Weighted average exercise price

$1.66

1.71

$2.28

2.35

$2.95

3.04

$3.74

3.85

$4.40

4.53

$5.12

5.27

$7.23

7.45

$3.96

4.08

Note_5_Share_Capital_Details_N

Note 5 - Share Capital (Details) - Non-Vested Stock Option Activity	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013
	USD ($)	CAD
Non-Vested Stock Option Activity [Abstract]	'	'
Non-vested at December 31, 2012	333,691	333,691
Non-vested at December 31, 2012	$3.38	3.38
Options granted	270,250	270,250
Options granted	$7.30	7.52
Options vested	-219,966	-219,966
Options vested	$4.34	4.47
Non-vested options forfeited	-30,300	-30,300
Non-vested options forfeited	$3.63	3.74
Non-vested at December 31, 2013	353,675	353,675
Non-vested at December 31, 2013	$5.28	5.44

Note_5_Share_Capital_Details_W

Note 5 - Share Capital (Details) - Weighted Average Option Pricing Assumptions	1 Months Ended	12 Months Ended
	Jun. 22, 2011	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
		USD ($)	CAD	2007 Plan And 2011 Plan [Member]	2007 Plan And 2011 Plan [Member]	2007 Plan And 2011 Plan [Member]
				CAD	CAD	CAD
Note 5 - Share Capital (Details) - Weighted Average Option Pricing Assumptions [Line Items]	'	'	'	'	'	'
Dividend yield	'	'	'	0.00%	0.00%	0.00%
Expected volatility	'	'	'	111.61%	120.40%	116.26%
Risk-free interest rate	'	'	'	2.39%	1.56%	2.51%
Expected average option term (years)	'10 years	'	'	'9 years 219 days	'8 years 73 days	'9 years 219 days
Fair value of options granted (C$) (in Dollars per share)	'	$7.30	7.52	6.96	3.83	2

Note_5_Share_Capital_Details_L

Note 5 - Share Capital (Details) - Location Of Expenses for Stock-Based Compensation (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Research, development, collaborations and contracts expenses	$21,458,258	$18,043,356	$20,131,922
General and administrative expenses	5,546,273	8,140,779	6,386,386
Total	903,005	982,290	633,449
2007 Plan And 2011 Plan [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Research, development, collaborations and contracts expenses	621,807	772,367	500,425
General and administrative expenses	$281,198	$209,923	$133,024

Note_5_Share_Capital_Details_O

Note 5 - Share Capital (Details) - Outstanding Options Under the Protiva Option Plan

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

USD ($)

CAD

Total [Member]

Exercised [Member]

Forfeited, Cancelled or Expired [Member]

EquivalentNumberOfCompanyCommonSharesMember

Protiva Share Options [Member]

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

EquivalentNumberOfCompanyCommonSharesMember

Protiva Share Options [Member]

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

EquivalentNumberOfCompanyCommonSharesMember

Protiva Share Options [Member]

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

Protiva Share Options [Member]

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

Protiva Share Options [Member]

USD ($)

CAD

USD ($)

CAD

USD ($)

CAD

Protiva Share Options [Member]

USD ($)

CAD

Note 5 - Share Capital (Details) - Outstanding Options Under the Protiva Option Plan [Line Items]

Number of Protiva Options

1,730,765

319,274

321,299

331,517

349,883

472,885

475,885

491,020

518,223

1,648,846

1,413,318

1,083,432

-1,350

-10,218

-18,366

-2,000

-15,135

-27,202

-124,246

-28,417

-1,667

-675

-1,000

-64,085

-62,355

-71,547

Equivalent number of Company common shares

1,730,765

319,274

321,299

331,517

349,883

472,885

475,885

491,020

518,223

1,648,846

1,413,318

1,083,432

-1,350

-10,218

-18,366

-2,000

-15,135

-27,202

-124,246

-28,417

-1,667

-675

-1,000

-64,085

-62,355

-71,547

Weighted average exercise price (in Dollars per share and Dollars per share)

$4.32

4.45

$0.29

0.3

$0.30

0.3

$0.30

0.3

$0.30

0.3

$4.54

4.54

$5.38

5.32

$7.72

7.95

$0.29

0.3

$0.30

0.3

$0.30

0.3

$3.13

3.22

$2.34

2.34

$1.52

1.5

$0.29

0.3

$21.23

21.87

$21.29

21.27

$27.74

27.42

Note_6_Government_Grants_and_R1

Note 6 - Government Grants and Refundable Investment Tax Credits (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Government Grants And Refundable Investment Tax Credits [Abstract]	'	'	'
Revenue from Grants	$68,633	$274,254	$344,744
Investment Tax Credit	$42,804	'	$21,150

Note_7_Income_Taxes_Details

Note 7 - Income Taxes (Details)	1 Months Ended	12 Months Ended							1 Months Ended
	Nov. 23, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Nov. 23, 2011
		USD ($)	USD ($)	USD ($)	Investment Tax Credit Carryforward [Member]	Investment Tax Credit Carryforward [Member]	Research Tax Credit Carryforward [Member]	Research Tax Credit Carryforward [Member]	Maximum [Member]
					USD ($)	USD ($)	USD ($)	USD ($)	CAD
Note 7 - Income Taxes (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	'	17.70%	17.50%	26.50%	'	'	'	'	'
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	'	'	'	'	$6,859,352	$5,891,094	'	'	'
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	'	'	'	'	2,431,691	1,914,623	'	'	'
Deferred Tax Assets, Operating Loss Carryforwards	'	4,354,066	4,561,144	'	'	'	49,906,852	48,357,146	'
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	'	'	'	'	'	'	24,526,593	21,457,451	'
Patent Tax Refund Percentage	75.00%	'	'	'	'	'	'	'	'
Proceeds from Income Tax Refunds (in Dollars)	'	$9,875	$322,720	$103,664	'	'	'	'	8,000,000

Note_7_Income_Taxes_Details_In

Note 7 - Income Taxes (Details) - Income Tax Reconciliation (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Reconciliation [Abstract]	'	'	'
Computed taxes (recoveries) at Canadian federal and provincial tax rates	($2,380,267)	$7,486,268	($2,589,310)
Differences due to change in enacted tax rates	-5,723	780,963	700,342
Difference due to change in tax rate on opening deferred taxes	'	2,636,377	3,369,825
Permanent and other differences	1,820,842	2,202,291	141,587
Change in valuation allowance	565,147	-2,515,765	-1,622,445
Utilization of investment tax credits	'	($10,590,133)	'

Note_7_Income_Taxes_Details_De

Note 7 - Income Taxes (Details) - Deferred Tax Assets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred Tax Assets [Abstract]	'	'
Non-capital loss carryforwards	$4,354,066	$4,561,144
Research and development deductions	8,858,564	8,583,554
Book amortization in excess of tax	2,170,922	1,934,818
Share issue costs	-136,329	-26,133
Revenue recognized for tax purposes in excess of revenue recognized for accounting purposes	667,542	'
Tax value in excess of accounting value in lease inducements	-2,821	8,041
Accounting value in excess of tax value in intangible assets	'	372,892
Provincial investment tax credits	392,063	304,545
Total deferred tax assets	16,304,008	15,738,861
Valuation allowance	($16,304,008)	($15,738,861)

Note_8_Contingencies_and_Commi1

Note 8 - Contingencies and Commitments (Details)

0 Months Ended

1 Months Ended

12 Months Ended

Nov. 12, 2012

Mar. 31, 2004

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2014

8-May-13

Jul. 14, 2010

Dec. 31, 2013

Mar. 25, 2008

Dec. 31, 2012

USD ($)

CAD

USD ($)

CAD

USD ($)

Marqibo [Member]

Protiva [Member]

Merck [Member]

Up-front Payment Arrangement [Member]

Research and Development [Member]

USD ($)

Note 8 - Contingencies and Commitments (Details) [Line Items]

Operating Leases, Future Minimum Payments Due

$705,150

Operating Leases, Rent Expense, Net

1,224,794

937,365

944,457

Operating Leases, Income Statement, Sublease Revenue

172,034

196,555

Percent of Costs Funded by TPC

27.00%

Maximum Contribution for Product

7,179,170

9,329,912

Cumulative Contribution for Product

3,480,217

3,701,571

Royalty Guarantees Commitments Percentage

2.50%

Royalty Revenue

39,581

Royalty Payable

990

Dividends Payable

12,000,000

Potential Contract Funding Amount

41,700,000

34,700,000

12,000,000

License Costs

300,000

8,500,000

100,000

450,000

Upfront Fee

200,000

300,000

Milestone Payment

$3,250,000

Note_9_Concentrations_of_Busin2

Note 9 - Concentrations of Business Risk (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Nov. 30, 2012
Note 9 - Concentrations of Business Risk (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Foreign Exchange Forward [Member]
Note 9 - Concentrations of Business Risk (Details) [Line Items]	'	'	'
Accounts Receivable, Net	$116,556	$1,074,891	'
Forward Exchange Contract	'	'	$45,000,000

Note_9_Concentrations_of_Busin3

Note 9 - Concentrations of Business Risk (Details) - Net Liquidity of the Company (USD $)	Dec. 31, 2013	Dec. 31, 2012
Net Liquidity of the Company [Abstract]	'	'
Cash, cash equivalents and short term investments	$68,716,531	$47,024,124
Less: Accounts payable and accrued liabilities	-3,680,462	-3,795,546
	$65,036,069	$43,228,578

Note_9_Concentrations_of_Busin4

Note 9 - Concentrations of Business Risk (Details) - Foreign Currency Exposure	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2013	Dec. 31, 2012
	USD ($)	CAD	USD ($)	CAD	USD ($)	USD ($)	Foreign Currency Exposure [Member]	Foreign Currency Exposure [Member]
							USD ($)	USD ($)
Intercompany Foreign Currency Balance [Line Items]	'	'	'	'	'	'	'	'
Cash and cash equivalents	$68,716,531	68,716,531	$47,024,124	47,024,124	$9,030,759	$12,412,678	$38,900,944	$149,058
Accounts receivable	116,556	'	1,074,891	'	'	'	10,840	1,025,306
Accrued revenue	'	212,384	'	2,373,881	'	'	225,892	2,361,836
Accounts payable and accrued liabilities	3,680,462	'	3,795,546	'	'	'	-1,889,480	-2,969,454
	$37,248,196	'	$566,746	'	'	'	'	'

Note_10_Supplementary_Informat2

Note 10 - Supplementary Information (Details) - Accounts Payable and Accrued Liabilities (USD $)	Dec. 31, 2013	Dec. 31, 2012
Note 10 - Supplementary Information (Details) - Accounts Payable and Accrued Liabilities [Line Items]	'	'
Accounts Payable and Accrued Liabilities	$3,680,462	$3,795,546
Trade Accounts Payable [Member]	'	'
Note 10 - Supplementary Information (Details) - Accounts Payable and Accrued Liabilities [Line Items]	'	'
Accounts Payable and Accrued Liabilities	1,217,242	805,790
Research and Development Accruals [Member]	'	'
Note 10 - Supplementary Information (Details) - Accounts Payable and Accrued Liabilities [Line Items]	'	'
Accounts Payable and Accrued Liabilities	1,404,905	310,492
License Fee Accruals [Member]	'	'
Note 10 - Supplementary Information (Details) - Accounts Payable and Accrued Liabilities [Line Items]	'	'
Accounts Payable and Accrued Liabilities	'	1,649,957
Professional Fee Accruals [Member]	'	'
Note 10 - Supplementary Information (Details) - Accounts Payable and Accrued Liabilities [Line Items]	'	'
Accounts Payable and Accrued Liabilities	247,148	602,113
Deferred Lease Inducements [Member]	'	'
Note 10 - Supplementary Information (Details) - Accounts Payable and Accrued Liabilities [Line Items]	'	'
Accounts Payable and Accrued Liabilities	16,454	48,078
Other Accrued Liabilities [Member]	'	'
Note 10 - Supplementary Information (Details) - Accounts Payable and Accrued Liabilities [Line Items]	'	'
Accounts Payable and Accrued Liabilities	$794,713	$379,116

Note_11_Subsequent_Events_Deta

Note 11 - Subsequent Events (Details) (Subsequent Event [Member], USD $)	1 Months Ended
	Jan. 31, 2014	Feb. 20, 2014	Jan. 13, 2014
Subsequent Event [Member]	'	'	'
Note 11 - Subsequent Events (Details) [Line Items]	'	'	'
Licensing Agreement Period	'	'	'4 years
Maximum Potential Transaction Value	'	'	$86,200,000
Proceeds from License Fees Received	14,500,000	'	'
Near Term Contract Payments	16,500,000	'	'
Potential Shelf Registration Offering Amount	'	$150,000,000	'
Period Of Shelf Registration	'	'25 years	'

Note_12_Interim_Financial_Data2

Note 12 - Interim Financial Data (unaudited) (Details) - Quarterly Interim Financial Data (unaudited) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Note 12 - Interim Financial Data (unaudited) (Details) - Quarterly Interim Financial Data (unaudited) [Line Items]	'	'	'
Revenue	$15,464,150	$14,105,186	$16,811,590
Loss from operations	-12,153,218	-12,944,548	-10,693,650
Net (loss) income	-14,064,226	29,611,996	-10,083,491
Basic net (loss) income per share (in Dollars per share)	($0.92)	$2.16	($0.89)
Diluted net (loss) income per share (in Dollars per share)	($0.92)	$2.07	($0.89)
Basic and diluted net loss per share (in Dollars per share)	($0.92)	'	'
Quarter One [Member]	'	'	'
Note 12 - Interim Financial Data (unaudited) (Details) - Quarterly Interim Financial Data (unaudited) [Line Items]	'	'	'
Revenue	2,131,519	3,586,970	'
Loss from operations	-2,993,811	-2,651,931	'
Net (loss) income	-2,546,244	-3,180,259	'
Basic net (loss) income per share (in Dollars per share)	'	($0.25)	'
Diluted net (loss) income per share (in Dollars per share)	'	($0.25)	'
Basic and diluted net loss per share (in Dollars per share)	($0.18)	'	'
Quarter Two [Member]	'	'	'
Note 12 - Interim Financial Data (unaudited) (Details) - Quarterly Interim Financial Data (unaudited) [Line Items]	'	'	'
Revenue	2,843,806	3,643,296	'
Loss from operations	-3,070,968	-2,599,027	'
Net (loss) income	-3,014,928	-1,935,761	'
Basic net (loss) income per share (in Dollars per share)	'	($0.14)	'
Diluted net (loss) income per share (in Dollars per share)	'	($0.14)	'
Basic and diluted net loss per share (in Dollars per share)	($0.21)	'	'
Quarter Three [Member]	'	'	'
Note 12 - Interim Financial Data (unaudited) (Details) - Quarterly Interim Financial Data (unaudited) [Line Items]	'	'	'
Revenue	2,962,809	3,067,593	'
Loss from operations	-3,652,191	-1,784,666	'
Net (loss) income	-5,905,923	-3,457,600	'
Basic net (loss) income per share (in Dollars per share)	'	($0.25)	'
Diluted net (loss) income per share (in Dollars per share)	'	($0.25)	'
Basic and diluted net loss per share (in Dollars per share)	($0.41)	'	'
Quarter Four [Member]	'	'	'
Note 12 - Interim Financial Data (unaudited) (Details) - Quarterly Interim Financial Data (unaudited) [Line Items]	'	'	'
Revenue	7,526,016	3,807,327	'
Loss from operations	-2,436,248	-5,908,924	'
Net (loss) income	($2,597,131)	$38,185,616	'
Basic net (loss) income per share (in Dollars per share)	'	$2.72	'
Diluted net (loss) income per share (in Dollars per share)	'	$2.51	'
Basic and diluted net loss per share (in Dollars per share)	($0.15)	'	'